,Headlines,Links
0,"Cipla, DNDi launch 4-in-1 antiretroviral treatment for children with HIV",https://www.moneycontrol.com/news/business/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-children-with-hiv-8685641.html
1,Accumulate Cipla; target of Rs 1020: KR Choksey,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-target-of-rs-1020-kr-choksey-8500101.html
2,Buy Cipla; target of Rs 1095: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1095-icici-direct-8490611.html
3,Neutral Cipla; target of Rs 880: Motilal Oswal,https://www.moneycontrol.com/news/business/stocks/neutral-cipla-target-of-rs-880-motilal-oswal-8488731.html
4,Buy Cipla; target of Rs 1085: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1085-prabhudas-lilladher-8488211.html
5,Buy Cipla: target of Rs 1150: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1150-sharekhan-3-8487211.html
6,Cipla: Targets for US complex generics on track,https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-targets-for-us-complex-generics-on-track-8493741.html
7,As Cipla falls after earnings; should you buy or sell stock?,https://www.moneycontrol.com/news/business/stocks/as-cipla-falls-after-earnings-should-you-buy-or-sell-stock-8485681.html
8,"Cipla Standalone March 2022 Net Sales at Rs 2,946.61 crore, down 8.86% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-march-2022-net-sales-at-rs-2946-61-crore-down-8-86-y-o-y-8486191.html
9,"Cipla Consolidated March 2022 Net Sales at Rs 5,260.33 crore, up 14.19% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-march-2022-net-sales-at-rs-5260-33-crore-up-14-19-y-o-y-8486351.html
10,Cipla inks pact with Genes2Me to launch COVID-19 RT PCR test kit,https://www.moneycontrol.com/news/business/cipla-inks-pact-with-genes2me-to-launch-covid-19-rt-pcr-test-kit-8480791.html
11,Cipla Q4 PAT seen up 27.6% YoY to Rs 527.6 cr: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/cipla-q4-pat-seen-up-27-6-yoy-to-rs-527-6-cr-prabhudas-lilladher-8362171.html
12,Buy Cipla: target of Rs 1150: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1150-sharekhan-2-8305111.html
13,"Analysts initiate coverage on 5 stocks with buy rating, expect 14-39 percent returns",https://www.moneycontrol.com/news/business/markets/analysts-initiate-coverage-on-5-stocks-with-buy-rating-expect-14-39-percent-returns-8260901.html
14,"Pharma companies turn to acquisitions to build scale, gain an edge",https://www.moneycontrol.com/news/opinion/pharma-companies-turn-to-acquisitions-to-build-scale-gain-an-edge-8228221.html
15,"Trade Spotlight | What should investors do with GNFC, BGR Energy, Laurus Labs, Cipla and Gujarat Ambuja Exports today?",https://www.moneycontrol.com/news/business/markets/trade-spotlight-what-should-investors-do-with-gnfc-bgr-energy-laurus-labs-cipla-and-gujarat-ambuja-exports-today-8224711.html
16,Cipla shares tank as promoters trim stake in block deal,https://www.moneycontrol.com/news/business/markets/ciplas-stock-falls-ahead-of-promoters-block-deal-to-offload-minority-stake-8097481.html
17,"Cipla promoters to sell up to 2.5% of drugmaker today for Rs 1,844 crore",https://www.moneycontrol.com/news/business/markets/cipla-promoters-to-sell-up-to-2-5-of-drugmaker-today-for-rs-1844-crore-8097091.html
18,Cipla to pick up 32.49% stake in solar power firm,https://www.moneycontrol.com/news/business/cipla-to-buy-32-49-stake-in-solar-power-firm-8042671.html
19,Accumulate Cipla; target of Rs 998: KR Choksey,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-target-of-rs-998-kr-choksey-8026801.html
20,Buy Cipla; target of Rs 1100: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1100-icici-direct-8000511.html
21,"Cipla Consolidated December 2021 Net Sales at Rs 5,478.86 crore, up 6% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-december-2021-net-sales-at-rs-5478-86-crore-up-6-y-o-y-2-7996911.html
22,Cipla's US business scale-up places it firmly on growth path,https://www.moneycontrol.com/news/opinion/ciplas-us-business-scale-up-places-it-firmly-on-growth-path-7994571.html
23,"What should investors do with Cipla post Q3 earnings; buy, sell or hold?",https://www.moneycontrol.com/news/business/stocks/what-should-investors-do-with-cipla-post-q3-earnings-buy-sell-or-hold-7988921.html
24,"Cipla Consolidated December 2021 Net Sales at Rs 5,478.86 crore, up 6% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-december-2021-net-sales-at-rs-5478-86-crore-up-6-y-o-y-7985221.html
25,"Cipla Standalone December 2021 Net Sales at Rs 3,954.79 crore, up 5.98% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-december-2021-net-sales-at-rs-3954-79-crore-up-5-98-y-o-y-7984851.html
26,"Trade Spotlight | What should you do with Sharda Cropchem, Bandhan Bank, Lupin, Cipla, Global Education?",https://www.moneycontrol.com/news/business/markets/trade-spotlight-what-should-you-do-with-sharda-cropchem-bandhan-bank-lupin-cipla-global-education-7978661.html
27,Cipla Q3 PAT may dip 6.4% YoY to Rs 700.3 cr: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/cipla-q3-pat-may-dip-6-4-yoy-to-rs-700-3-cr-prabhudas-lilladher-7933201.html
28,Cipla gets EUA from DCGI to market Molnupiravir for COVID-19 treatment,https://www.moneycontrol.com/news/business/cipla-gets-eua-from-dcgi-to-market-molnupiravir-for-covid-19-treatment-7874641.html
29,"Hot Stocks | Here's why you should bet on Cipla, Coforge in near term",https://www.moneycontrol.com/news/business/markets/hot-stocks-heres-why-you-should-bet-on-cipla-coforge-in-near-term-7868041.html
30,"Trade Spotlight | What should you do with Future Retail, Cipla, Bajaj Finance, and SBI now?",https://www.moneycontrol.com/news/business/markets/trade-spotlight-what-should-you-do-with-future-retail-cipla-bajaj-finance-and-sbi-now-7847101.html
31,Cipla shares gain 2% on final FDA approval for Lanreotide injection,https://www.moneycontrol.com/news/business/stocks/cipla-shares-gain-2-on-final-fda-approval-for-lanreotide-injection-7843551.html
32,"Trade Spotlight | What should investors do with Indiabulls Housing Finance, Cipla, Meghmani Organics & BEML now?",https://www.moneycontrol.com/news/business/markets/trade-spotlight-what-should-investors-do-with-indiabulls-housing-finance-cipla-meghmani-organics-beml-now-7769261.html
33,Nykaa outgrows some India Inc giants in M-cap on D-street debut,https://www.moneycontrol.com/news/business/markets/nykaa-outgrows-some-india-inc-giants-in-m-cap-on-d-street-debut-7700941.html
34,Cipla unit gets notice from US firm for termination of acquisition deal,https://www.moneycontrol.com/news/business/cipla-unit-gets-notice-from-us-firm-for-termination-of-acquisition-deal-7675301.html
35,"Cipla Standalone September 2021 Net Sales at Rs 3,935.03 crore, up 3.34% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-september-2021-net-sales-at-rs-3935-03-crore-up-3-34-y-o-y-3-7650871.html
36,Lupin: Competitive pressure remains in the US market,https://www.moneycontrol.com/news/business/earnings/lupin-competitive-pressure-remains-in-the-us-market-7648241.html
37,"Cipla Standalone September 2021 Net Sales at Rs 3,935.03 crore, up 3.34% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-september-2021-net-sales-at-rs-3935-03-crore-up-3-34-y-o-y-2-7640301.html
38,"Cipla Consolidated September 2021 Net Sales at Rs 5,519.80 crore, up 9.56% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-september-2021-net-sales-at-rs-5519-80-crore-up-9-56-y-o-y-7639361.html
39,Buy Cipla: target of Rs 1150: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1150-sharekhan-7637071.html
40,"Cipla Standalone September 2021 Net Sales at Rs 3,935.03 crore, up 3.34% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-september-2021-net-sales-at-rs-3935-03-crore-up-3-34-y-o-y-7636781.html
41,Cipla: Focus shifts to FY23 launches,https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-focus-shifts-to-fy23-launches-7634511.html
42,"Nifty Q2 Result Preview: Watch out for Axis Bank, Kotak Bank, Bajaj Finance, Cipla",https://www.moneycontrol.com/news/business/nifty-q2-result-preview-watch-out-for-axis-bank-kotak-bank-bajaj-finance-cipla-7630071.html
43,Cipla Q2 PAT seen up 20.3% YoY to Rs 793.4 cr: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/cipla-q2-pat-seen-up-20-3-yoy-to-rs-793-4-cr-prabhudas-lilladher-7551471.html
44,Eli Lilly to transfer rights of two diabetes products to Cipla,https://www.moneycontrol.com/news/trends/current-affairs-trends/eli-lilly-to-transfer-rights-of-two-diabetes-products-to-cipla-7540101.html
45,Cipla partners Kemwell to foray into respiratory biosimilars space,https://www.moneycontrol.com/news/business/companies/cipla-partners-kemwell-to-foray-into-respiratory-biosimilars-space-7388871.html
46,Cipla gets USFDA nod for generic product,https://www.moneycontrol.com/news/business/companies/cipla-gets-usfda-nod-for-generic-product-7323271.html
47,"Cipla Consolidated June 2021 Net Sales at Rs 5,504.35 crore, up 26.65% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-june-2021-net-sales-at-rs-5504-35-crore-up-26-65-y-o-y-2-7307191.html
48,Buy Cipla; target of Rs 1205: ICICI Direct,https://www.moneycontrol.com/news/business/earnings/buy-cipla-target-of-rs-1205-icici-direct-7305041.html
49,"Cipla Standalone June 2021 Net Sales at Rs 4,017.41 crore, up 28.43% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-june-2021-net-sales-at-rs-4017-41-crore-up-28-43-y-o-y-2-7302751.html
50,Ideas For Profit | Cipla,https://www.moneycontrol.com/news/business/markets/ideas-for-profit-cipla-pharma-api-generic-medicines-green-chemistry-esg-digitisation-7289761.html
51,"Cipla Consolidated June 2021 Net Sales at Rs 5,504.35 crore, up 26.65% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-june-2021-net-sales-at-rs-5504-35-crore-up-26-65-y-o-y-7288311.html
52,Cipla: M&A opportunity could be near-term trigger,https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-ma-opportunity-could-be-near-term-trigger-7286311.html
53,"What should investors do with Cipla post Q1 earnings: buy, sell or hold?",https://www.moneycontrol.com/news/business/markets/what-should-investors-do-with-cipla-post-q1-earnings-buy-sell-or-hold-7285781.html
54,Cipla Q1 net profit up 25% to Rs 709.92 crore,https://www.moneycontrol.com/news/business/earnings/cipla-q1-net-profit-up-25-to-rs-709-92-crore-7284911.html
55,"Bajar Gupshup | Markets bounce back aided by metal, power, IT & realty stocks",https://www.moneycontrol.com/news/business/markets/bajar-gupshup-markets-bounce-back-aided-by-metal-power-it-realty-stocks-7208891.html
56,Cipla Q1 PAT seen up 10.9% YoY to Rs 640.7 cr: KRChoksey,https://www.moneycontrol.com/news/business/cipla-q1-pat-seen-up-10-9-yoy-to-rs-640-7-cr-krchoksey-7164821.html
57,Cipla Q1 PAT may dip 7.5% YoY to Rs 534.3 cr: ICICI Direct,https://www.moneycontrol.com/news/business/cipla-q1-pat-may-dip-7-5-yoy-to-rs-534-3-cr-icici-direct-7161581.html
58,How Erez Israeli revived Dr Reddy’s by focusing on costs and non-US markets,https://www.moneycontrol.com/news/opinion/how-erez-israeli-revived-dr-reddys-by-focusing-on-costs-and-non-us-markets-7144121.html
59,Cipla gets DCGI nod for import of Moderna COVID-19 vaccine: Reports,https://www.moneycontrol.com/news/india/cipla-gets-dcgi-nod-for-import-of-moderna-covid-19-vaccine-reports-7103251.html
60,Cipla hits 52-week high as company seeks DCGI nod to import Moderna's COVID jab,https://www.moneycontrol.com/news/business/stocks/cipla-hits-52-week-high-as-company-seeks-dcgi-nod-to-import-modernas-covid-jab-7103161.html
61,Cipla seeks DCGI nod to import Moderna's COVID-19 vaccine,https://www.moneycontrol.com/news/india/cipla-seeks-dcgi-nod-to-import-modernas-covid-19-vaccine-7101191.html
62,Cipla gets USFDA nod for inhalation product,https://www.moneycontrol.com/news/trends/health-trends/cipla-gets-usfda-nod-for-inhalation-product-7075911.html
63,"COVID-19 vaccine | Close to commit over $1billion to Moderna for booster vaccine; provide price capping waiver, indemnity: Cipla to Govt",https://www.moneycontrol.com/news/coronavirus/covid-19-vaccine-close-to-commit-over-1billion-to-moderna-for-booster-vaccine-provide-price-capping-waiver-indemnity-cipla-to-govt-6967441.html
64,"Ideas For Profit | Cadila: COVID opportunity, complex pharma pipeline offer strong risk reward",https://www.moneycontrol.com/news/business/ipo/ideas-for-profit-cadila-covid-opportunity-complex-pharma-pipeline-offer-strong-risk-reward-6957071.html
65,Cadila: All in for COVID while keeping a tab on complex pharma,https://www.moneycontrol.com/news/business/moneycontrol-research/cadila-all-in-for-covid-while-keeping-a-tab-on-complex-pharma-6953181.html
66,COVID-19 vaccine | Moderna's single-dose in India likely next year,https://www.moneycontrol.com/news/coronavirus/covid-19-vaccine-modernas-single-dose-in-india-likely-next-year-6938501.html
67,Buy Cipla; target of Rs 940: Dolat Capital Market,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-940-dolat-capital-market-2-6935471.html
68,Cipla launches RT-PCR test kit 'ViraGen' in India partnership with Ubio Biotech,https://www.moneycontrol.com/news/business/cipla-launches-rt-pcr-test-kit-viragen-in-india-partnership-with-ubio-biotech-6916981.html
69,Cipla share price gains on launching polymerase chain reaction test kit,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-gains-on-launching-polymerase-chain-reaction-test-kit-6916641.html
70,"Coronavirus pandemic | Cipla to expand portfolio for COVID-19 drugs over next two months, says CFO",https://www.moneycontrol.com/news/business/covid-19-cipla-to-expand-portfolio-for-covid-19-drugs-over-next-two-months-says-cfo-6902471.html
71,"Cipla — While COVID scope continues, watch out for FY23",https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-while-covid-scope-continues-watch-out-for-fy23-6901081.html
72,Cipla share price down 3% after Q4 earnings misses expectations,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-down-3-after-q4-earnings-misses-expectations-6900501.html
73,"Cipla Consolidated March 2021 Net Sales at Rs 4,606.45 crore, up 5.26% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-march-2021-net-sales-at-rs-4606-45-crore-up-5-26-y-o-y-6895101.html
74,"Cipla Standalone March 2021 Net Sales at Rs 3,233.12 crore, up 3.18% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-march-2021-net-sales-at-rs-3233-12-crore-up-3-18-y-o-y-6894991.html
75,"Cipla Q4 profit jumps 72% to Rs 411.5 crore, misses estimates on all earnings parameters",https://www.moneycontrol.com/news/business/earnings/cipla-q4-profit-jumps-72-to-rs-411-5-crore-misses-estimates-on-all-earnings-parameters-6894421.html
76,"Cipla, Jubilant to face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt",https://www.moneycontrol.com/news/india/cipla-jubilant-to-face-action-if-it-fails-to-fulfill-supply-obligation-of-remdesivir-within-24-hours-karnataka-govt-6881441.html
77,Government takes over allotment of critical COVID-19 drug Tocilizumab amid shortage,https://www.moneycontrol.com/news/business/companies/indian-govt-takes-over-allottment-of-critical-covid-19-drug-tocilizumab-amid-shortage-6827211.html
78,Buy Cipla: target of Rs 1100: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1100-sharekhan-2-6781711.html
79,COVID-19: Chhattisgarh govt mulls legal action against Cipla for not meeting Remdesivir supply requirements,https://www.moneycontrol.com/news/india/covid-19-chhattisgarh-govt-mulls-legal-action-against-cipla-for-not-meeting-remdesivir-supply-requirements-report-6791351.html
80,Cipla doubles Remdesivir production to meet 'unprecedented' demand,https://www.moneycontrol.com/news/trends/health-trends/cipla-doubles-remdesivir-production-to-meet-unprecedented-demand-6763951.html
81,Cipla Q4 PAT seen up 147.8% YoY to Rs. 609 cr: Sharekhan,https://www.moneycontrol.com/news/business/cipla-q4-pat-seen-up-147-8-yoy-to-rs-609-cr-sharekhan-6760781.html
82,What ‘second wave’ means for investors in Indian pharma,https://www.moneycontrol.com/news/business/moneycontrol-research/what-second-wave-means-for-investors-in-indian-pharma-6757201.html
83,"Cipla Gulf expands partnership with Alvotech for commercialisation of four drugs in Australia, New Zealand",https://www.moneycontrol.com/news/business/cipla-gulf-expands-partnership-with-alvotech-for-commercialisation-of-four-drugs-in-australia-new-zealand-6592431.html
84,Cipla gets USFDA nod for migraine drug,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-migraine-drug-6592371.html
85,Buy Cipla; target of Rs 940: Dolat Capital Market,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-940-dolat-capital-market-6469981.html
86,Buy Cipla; target of Rs 950: Sharekhan,https://www.moneycontrol.com/news/business/buy-cipla-target-of-rs-950-sharekhan-2-6469141.html
87,Accumulate Cipla; target of Rs 913: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-target-of-rs-913-prabhudas-lilladher-6448771.html
88,Buy Cipla; target of Rs 975: ICICI Direct,https://www.moneycontrol.com/news/business/buy-cipla-target-of-rs-975-icici-direct-6449241.html
89,Lupin: New launches and market share gains are likely to override pricing erosion,https://www.moneycontrol.com/news/business/moneycontrol-research/lupin-new-launches-and-market-share-gains-are-likely-to-override-pricing-erosion-6438411.html
90,Neutral Cipla; target of Rs 900: Motilal Oswal,https://www.moneycontrol.com/news/business/neutral-cipla-target-of-rs-900-motilal-oswal-6435951.html
91,Buy Cipla; target of Rs 1020: HDFC Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-1020-hdfc-securities-6432071.html
92,"Cipla Consolidated December 2020 Net Sales at Rs 5,168.69 crore, up 18.25% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-december-2020-net-sales-at-rs-5168-69-crore-up-18-25-y-o-y-6432471.html
93,"Cipla Standalone December 2020 Net Sales at Rs 3,731.55 crore, up 27.52% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-december-2020-net-sales-at-rs-3731-55-crore-up-27-52-y-o-y-6431431.html
94,Pharma: Ignore the noise as the core allocation is incremental,https://www.moneycontrol.com/news/business/moneycontrol-research/pharma-ignore-the-noise-as-the-core-allocation-is-incremental-6428521.html
95,Cipla — Large part of COVID opportunity has played out,https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-large-part-of-covid-opportunity-has-played-out-6421201.html
96,"Cipla posts strong Q3 numbers, profit more than doubles to Rs 748.15 crore",https://www.moneycontrol.com/news/business/markets/cipla-posts-strong-q3-numbers-profit-more-than-doubles-to-rs-748-15-crore-6416791.html
97,Cipla Q3 PAT seen up 74.3% YoY to Rs. 612 cr: Yash Securities,https://www.moneycontrol.com/news/business/earnings/cipla-q3-pat-seen-up-74-3-yoy-to-rs-612-cr-yash-securities-6383311.html
98,Cipla Q3 PAT seen up 77.2% YoY to Rs. 351 cr: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/earnings/cipla-q3-pat-seen-up-77-2-yoy-to-rs-351-cr-prabhudas-lilladher-6359251.html
99,Cipla Q3 PAT seen up 73.2% YoY to Rs. 608.1 cr: ICICI Direct,https://www.moneycontrol.com/news/business/cipla-q3-pat-seen-up-73-2-yoy-to-rs-608-1-cr-icici-direct-6362501.html
100,Will normalcy return to COVID-hit Indian pharmaceutical market in 2021?,https://www.moneycontrol.com/news/business/will-normalcy-return-to-covid-hit-indian-pharmaceutical-market-in-2021-6238531.html
101,Quant Pick - Cipla: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/quant-pick-cipla-icici-direct-6257751.html
102,Cipla share price gains on launching rapid antigen detection test,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-gains-on-launching-rapid-antigen-detection-test-6233121.html
103,Buy Cipla; target of Rs 940: HDFC Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-940-hdfc-securities-6224801.html
104,Buy Cipla; target of Rs 887: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-887-prabhudas-lilladher-6224771.html
105,Cipla share price jumps 5% after settlement with Celgene Corp,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-jumps-5-after-settlement-with-celgene-corp-6223011.html
106,Hold Cipla; target of Rs 836: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-836-prabhudas-lilladher-6104641.html
107,Buy Cipla: target of Rs 950: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-950-sharekhan-6098581.html
108,Indian demand for COVID-19 drug Remdesivir rising sharply: Cipla,https://www.moneycontrol.com/news/trends/health-trends/indian-demand-for-covid-19-drug-remdesivir-rising-sharply-cipla-6092271.html
109,Buy Cipla; target of Rs 942: Dolat Capital Market,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-942-dolat-capital-market-6088681.html
110,Buy Cipla; target of Rs 925: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-925-icici-direct-6088881.html
111,Cipla: Covid opportunity and traction for Albuterol strong positives; accumulate,https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-covid-opportunity-and-traction-for-albuterol-strong-positives-accumulate-6089811.html
112,Cipla asks its IT team to be on alert after cyber attacks on major pharma firms,https://www.moneycontrol.com/news/business/cipla-asks-its-it-team-to-be-on-alert-after-cyber-attacks-on-major-pharma-firms-6089121.html
113,Looking at sustaining growth through pandemic: Cipla,https://www.moneycontrol.com/news/business/looking-at-sustaining-growth-through-pandemic-cipla-6088241.html
114,"Cipla Q2 earnings beat street estimates; profit spikes 38% to Rs 662 crore, India sales up 17%",https://www.moneycontrol.com/news/business/earnings/cipla-q2-earnings-beat-street-estimates-profit-spikes-38-to-rs-662-crore-india-sales-up-17-6079681.html
115,"Cipla gets into COVID-19 testing, with the launch of antibody test kits",https://www.moneycontrol.com/news/business/companies/cipla-gets-into-covid-19-testing-with-the-launch-of-antibody-test-kits-6029971.html
116,Reduce Cipla; target of Rs 657: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/stocks/reduce-cipla-target-of-rs-657-prabhudas-lilladher-2-5960981.html
117,"Cipla to acquire US inhaler-maker for Rs 1,000 crore",https://www.moneycontrol.com/news/business/stocks/cipla-to-acquire-us-inhaler-maker-for-rs-1000-crore-5884681.html
118,Cadila: a formidable play in Covid times and beyond,https://www.moneycontrol.com/news/business/moneycontrol-research/cadila-a-formidable-play-in-covid-times-and-beyond-5882731.html
119,Cipla share price gains 4% on USFDA approval for multiple sclerosis drug,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-gains-4-on-usfda-approval-for-multiple-sclerosis-drug-5882281.html
120,"Perrigo’s pain is a windfall for Cipla, Lupin",https://www.moneycontrol.com/news/business/moneycontrol-research/perrigos-pain-is-a-windfall-for-cipla-lupin-5855661.html
121,"Lupin shares hit 52-week high, Cipla shares jump 6% after Perrigo recalls albuterol sulfate",https://www.moneycontrol.com/news/business/markets/lupin-shares-hit-52-week-high-cipla-shares-jump-6-after-perrigo-recalls-albuterol-sulfate-5855331.html
122,Lupin: At the inflection point for complex generics,https://www.moneycontrol.com/news/business/moneycontrol-research/lupin-at-the-inflection-point-for-complex-generics-5756991.html
123,Buy Cipla; target of Rs 894 KRChoksey,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-894-krchoksey-5693031.html
124,Covid-19 vaccine: Cipla scales up manufacturing of remdesivir to meet high demand,https://www.moneycontrol.com/news/business/companies/cipla-scales-up-manufacturing-of-remdesivir-to-meet-high-demand-5684851.html
125,Neutral Cipla; target of Rs 790: Motilal Oswal,https://www.moneycontrol.com/news/business/stocks/neutral-cipla-target-of-rs-790-motilal-oswal-5678631.html
126,Buy Cipla; target of Rs 805: HDFC Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-805-hdfc-securities-5678821.html
127,Reduce Cipla; target of Rs 657: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/stocks/reduce-cipla-target-of-rs-657-prabhudas-lilladher-5678931.html
128,Buy Cipla; target of Rs 900: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-900-icici-direct-5671581.html
129,"Cipla Consolidated June 2020 Net Sales at Rs 4,346.16 crore, up 8.95% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-june-2020-net-sales-at-rs-4346-16-crore-up-8-95-y-o-y-5673871.html
130,"Cipla shares jump after Q1 earnings beat estimates; Citi upgrades to buy, Morgan Stanley remains overweight",https://www.moneycontrol.com/news/business/stocks/cipla-shares-jump-after-q1-earnings-beat-estimates-citi-upgrades-to-buy-morgan-stanley-remains-overweight-5672471.html
131,"Cipla Standalone June 2020 Net Sales at Rs 3,128.02 crore, down 3.14% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-june-2020-net-sales-at-rs-3128-02-crore-down-3-14-y-o-y-5673041.html
132,Prospects for US business and leadership in respiratory therapies make Cipla attractive,https://www.moneycontrol.com/news/business/moneycontrol-research/prospects-for-us-business-and-leadership-in-respiratory-therapies-make-cipla-attractive-5671191.html
133,Accumulate Cipla; target of Rs 804: Dolat Capital,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-target-of-rs-804-dolat-capital-5669701.html
134,Buy Cipla; target of Rs 875: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-875-sharekhan-5665221.html
135,"Cipla Q1 profit jumps 27% YoY to Rs 566 crore, beats analysts' expectations",https://www.moneycontrol.com/news/business/earnings/cipla-q1-profit-jumps-27-yoy-to-rs-566-crore-beats-analysts-expectations-5661971.html
136,Collaborating with govt agencies to develop treatment for COVID-19: Cipla,https://www.moneycontrol.com/news/business/collaborating-with-govt-agencies-to-develop-treatment-for-covid-19-cipla-5649881.html
137,Three senior executives exit Cipla's India unit,https://www.moneycontrol.com/news/business/three-senior-executives-exit-ciplas-india-unit-5642851.html
138,'Expect a tepid start for Nifty on Monday; but these 3 bets can return 11-12%',https://www.moneycontrol.com/news/business/markets/expect-a-tepid-start-for-nifty-on-monday-but-these-3-bets-can-return-11-12-5630031.html
139,Coronavirus India | Cipla to soon launch COVID-19 drug Ciplenza at Rs 68 per tablet,https://www.moneycontrol.com/news/india/coronavirus-india-cipla-to-soon-launch-covid-19-drug-ciplenza-at-rs-68-per-tablet-5594501.html
140,Gladiator Stocks - Cipla: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/gladiator-stocks-cipla-icici-direct-5567441.html
141,"Cipla, Amgen settle legal dispute in cinacalcet tablets case",https://www.moneycontrol.com/news/business/cipla-amgen-settle-legal-dispute-in-cinacalcet-tablets-case-5569661.html
142,Cipla gets USFDA nod for rare genetic condition treatment drug,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-rare-genetic-condition-treatment-drug-5544991.html
143,Cipla share price rises on USFDA nod; surges 45% in 9 months,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-rises-on-usfda-nod-surges-45-in-9-months-5544351.html
144,Coronavirus treatment | Cipla ramps up remdesivir capacity to meet surge in demand,https://www.moneycontrol.com/news/trends/health-trends/coronavirus-treatment-cipla-ramps-up-remdesivir-capacity-to-meet-surge-in-demand-5539531.html
145,Cipla launches generic version of remdesivir in India,https://www.moneycontrol.com/news/business/cipla-launches-generic-version-of-remdesivir-in-india-5525081.html
146,"Cipla, Boehringer Ingelheim to co-market 3 oral anti-diabetic drugs",https://www.moneycontrol.com/news/business/companies/cipla-boehringer-ingelheim-to-co-market-3-oral-anti-diabetic-drugs-5476211.html
147,Cipla shares gain 2% on partnership with a German firm for anti-diabetic drugs,https://www.moneycontrol.com/news/business/markets/cipla-shares-gain-2-on-partnership-with-a-german-firm-for-anti-diabetic-drugs-5475871.html
148,CSIR will now focus on clinical trial of combinations of drugs for COVID-19 treatment,https://www.moneycontrol.com/news/coronavirus/csir-will-now-focus-on-clinical-trial-of-combinations-of-drugs-for-covid-19-treatment-5450821.html
149,"Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial",https://www.moneycontrol.com/news/business/cipla-to-price-generic-version-of-covid-19-drug-remdesivir-at-less-than-rs-5000-per-vial-5446881.html
150,"Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID fight, say medical experts",https://www.moneycontrol.com/news/trends/health-trends/remdesiver-favipiravir-antiviral-drugs-no-game-changers-in-covid-fight-say-medical-experts-5440511.html
151,"Big Story | Cipla, Hetero get regulator nod for Remdesivir: What this means for COVID-19 patients",https://www.moneycontrol.com/news/eye-on-india/videos/big-story-cipla-hetero-get-regulator-nod-for-remdesivir-what-this-means-for-covid-19-patients-5439111.html
152,Cipla shares end almost 3% higher on regulator nod to manufacture remdesivir,https://www.moneycontrol.com/news/business/stocks/cipla-shares-spike-7-on-regulator-nod-to-manufacture-remdesivir-5437351.html
153,Cipla share price rises as it expands partnership with Roche Pharma,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-rises-as-it-expands-partnership-with-roche-pharma-5426251.html
154,Cipla to acquire 21.85% stake in GoApptiv,https://www.moneycontrol.com/news/business/cipla-to-acquire-21-85-stake-in-goapptiv-5384941.html
155,Buy Cipla target of Rs 738: Anand Rathi,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-738-anand-rathi-5327791.html
156,Cipla gets final nod from USFDA for migraine treatment nasal spray,https://www.moneycontrol.com/news/business/cipla-gets-final-nod-from-usfda-for-migraine-treatment-nasal-spray-5295781.html
157,"Cipla Consolidated March 2020 Net Sales at Rs 4,376.19 crore, down 0.63% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-march-2020-net-sales-at-rs-4376-19-crore-down-0-63-y-o-y-2-5295521.html
158,COVID-19 treatment | Cipla eyes multi-drug portfolio for novel coronavirus cure: Report,https://www.moneycontrol.com/news/business/covid-19-treatment-cipla-eyes-multi-drug-portfolio-for-novel-coronavirus-cure-report-5285291.html
159,Buy Cipla; target of Rs 655: HDFC Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-655-hdfc-securities-5282241.html
160,Buy Cipla; target of Rs 670: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-670-icici-direct-5282191.html
161,"Cipla Consolidated March 2020 Net Sales at Rs 4,376.19 crore, down 0.63% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-march-2020-net-sales-at-rs-4376-19-crore-down-0-63-y-o-y-5281621.html
162,"Cipla: Respiratory pipeline adds oxygen, accumulate",https://www.moneycontrol.com/news/business/moneycontrol-research/cipla-respiratory-pipeline-adds-oxygen-accumulate-5279491.html
163,Cipla submits application with USFDA for generic version of asthma drug,https://www.moneycontrol.com/news/business/cipla-submits-application-with-usfda-for-generic-version-of-asthma-drug-5280561.html
164,Cipla share price gains 2% on Q4 numbers; files application for asthma drug with USFDA,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-gains-2-on-q4-numbers-files-application-for-asthma-drug-with-usfda-5280171.html
165,Buy Cipla target of Rs 650: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-650-sharekhan-2-5278571.html
166,"Cipla reports Q4 profit at Rs 246 crore, FY20 net grows 1% to Rs 1,547 crore",https://www.moneycontrol.com/news/business/earnings/cipla-reports-q4-profit-at-rs-246-crore-revenue-at-rs-4302-crore-5271061.html
167,"Cipla Q4 profit, revenue could decline due to high-base effect",https://www.moneycontrol.com/news/business/earnings/cipla-q4-profit-revenue-could-decline-due-to-high-base-effect-5269201.html
168,Cipla share price rises nearly 6% on partnership with Gilead for COVID-19 treatment,https://www.moneycontrol.com/news/business/cipla-share-price-rises-nearly-6-on-partnership-with-gilead-for-covid-19-treatment-5258771.html
169,Cipla pledges Rs 25 crore donation to government for fighting COVID-19 crisis,https://www.moneycontrol.com/news/business/cipla-pledges-rs-25-crore-donation-to-government-for-fighting-covid-19-crisis-5171481.html
170,US FDA tailwind: Structural or situational?,https://www.moneycontrol.com/news/business/moneycontrol-research/us-fda-tailwind-structural-or-situational-5169801.html
171,Pharma companies that can benefit from the demand for complex respiratory drugs,https://www.moneycontrol.com/news/business/markets/pharma-companies-that-can-benefit-from-the-demand-for-complex-respiratory-drugs-5157301.html
172,"Cipla Health partners Swiggy, Zomato, Dunzo for home delivery of OTC wellness products",https://www.moneycontrol.com/news/business/cipla-health-partners-swiggy-zomato-dunzo-for-home-delivery-of-otc-wellness-products-5148541.html
173,Cipla share price hits 52-week high on final approval from US FDA,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-hits-52-week-high-on-final-approval-from-us-fda-5125071.html
174,Cipla share price up 8% on successful completion of Phase-3 clinical study of asthma drug,https://www.moneycontrol.com/news/business/markets/cipla-share-price-up-8-on-successful-completion-of-phase-3-clinical-study-of-asthma-drug-5104691.html
175,Cipla gets USFDA nod for generic acid reflux drug,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-generic-acid-reflux-drug-5075231.html
176,Cipla share price gains over 3% on USFDA approval,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-gains-over-3-on-usfda-approval-5074161.html
177,USFDA issues warning letter to Cipla for Goa plant,https://www.moneycontrol.com/news/business/usfda-issues-warning-letter-to-cipla-for-goa-plant-5048611.html
178,"Coronavirus pandemic | Pharma, cosmetics makers switch to hand sanitisers as demand rockets",https://www.moneycontrol.com/news/business/coronavirus-pandemic-as-demand-rockets-pharma-cosmetics-makers-switch-to-hand-sanitisers-5042581.html
179,"Slideshow | Cipla, IRB Infra among 5 stocks that can give 17-39% return",https://www.moneycontrol.com/news/photos/business/stocks/slideshow-cipla-irb-infra-among-5-stocks-that-can-give-17-39-return-4982681.html
180,USFDA issues warning letter to Cipla for Goa manufacturing facility,https://www.moneycontrol.com/news/business/usfda-issues-warning-letter-to-cipla-for-goa-manufacturing-facility-4978591.html
181,Cipla share price falls 5% on warning letter from USFDA,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-falls-5-on-warning-letter-from-usfda-4978051.html
182,Hold Cipla; target of Rs 490: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-490-icici-direct-4930601.html
183,Cipla share price rises on distribution agreement for antipsychotic drug,https://www.moneycontrol.com/news/business/markets/cipla-share-price-rises-on-distribution-agreement-for-antipsychotic-drug-4930401.html
184,Buy Cipla target of Rs 540: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-540-sharekhan-2-4925761.html
185,"Cipla Consolidated December 2019 Net Sales at Rs 4,371.00 crore, up 9.07% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-december-2019-net-sales-at-rs-4371-00-crore-up-9-07-y-o-y-4918561.html
186,"Cipla Standalone December 2019 Net Sales at Rs 2,926.20 crore, up 3.21% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-december-2019-net-sales-at-rs-2926-20-crore-up-3-21-y-o-y-4918301.html
187,Cipla share price rises as Nomura upgrades to buy,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-rises-as-nomura-upgrades-to-buy-4917671.html
188,"Cipla sees recovery in emerging markets in Q4FY20, here are highlights of analyst call",https://www.moneycontrol.com/news/business/earnings/cipla-sees-recovery-in-emerging-markets-in-q4fy20-here-are-highlights-of-analyst-call-4912601.html
189,"What should investors do with Cipla post Q3: buy, sell or hold?",https://www.moneycontrol.com/news/business/stocks/what-should-investors-do-with-cipla-post-q3-buy-sell-or-hold-4912201.html
190,"Cipla rejigs India biz, integrates domestic, generics and consumer divisions",https://www.moneycontrol.com/news/business/companies/cipla-rejigs-india-biz-integrates-domestic-generics-and-consumer-divisions-4910891.html
191,"Cipla Q3 profit rises 5.7% to Rs 351 cr, but operating margin contracts",https://www.moneycontrol.com/news/business/earnings/cipla-q3-profit-rises-5-7-to-rs-351-cr-but-operating-margin-contracts-4909601.html
192,Deleveraging and deals – a healthy prescription for pharma sector,https://www.moneycontrol.com/news/opinion/deleveraging-and-deals-a-healthy-prescription-for-pharma-sector-4870891.html
193,Cipla gets EIR from USFDA for Invagen manufacturing facility,https://www.moneycontrol.com/news/business/cipla-gets-eir-from-usfda-for-invagen-manufacturing-facility-4866051.html
194,Cipla share price falls 2% post USFDA observations,https://www.moneycontrol.com/news/business/cipla-share-price-falls-2-post-usfda-observations-4847101.html
195,Cipla gets USFDA observations for its Goa facility,https://www.moneycontrol.com/news/business/cipla-gets-usfda-observations-for-its-goa-facility-4846881.html
196,Mitsubishi UFJ Financial sells 2.10% shares in Cipla,https://www.moneycontrol.com/news/business/mitsubishi-ufj-financial-sells-2-10-shares-in-cipla-4838651.html
197,Cipla announces closure of USFDA inspection at Patalganga facility,https://www.moneycontrol.com/news/business/cipla-announces-closure-of-usfda-inspection-at-patalganga-facility-4833711.html
198,Cipla share price up nearly 2% on trademark acquisition of anti-diabetic drug,https://www.moneycontrol.com/news/business/stocks/cipla-share-price-up-nearly-2-on-trademark-acquisition-of-anti-diabetic-drug-4737101.html
199,Exclusive | Cipla leads race for Wockhardt's business divisions,https://www.moneycontrol.com/news/business/exclusive-cipla-leads-race-for-wockhardts-business-divisions-4685781.html
200,Don’t miss! Stocks from life insurance and AMC likely to be included in Sensex & Nifty,https://www.moneycontrol.com/news/business/markets/dont-miss-stocks-from-life-insurance-and-amc-likely-to-be-included-in-sensex-nifty-4660891.html
201,"Exclusive | Cipla, Dr Reddy's, Carlyle and Hong Kong fund in fray for Wockhardt divisions",https://www.moneycontrol.com/news/business/companies/cipla-dr-reddys-carlyle-and-hong-kong-fund-in-fray-for-wockhardt-divisions-4643451.html
202,Buy Cipla target of Rs 540: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-540-sharekhan-4625951.html
203,Cipla expects to end FY20 with gross margins of 65-66% led by new launches in second half,https://www.moneycontrol.com/news/business/cipla-expects-to-end-fy20-with-gross-margins-of-65-66-led-by-new-launches-in-second-half-4617011.html
204,"Cipla Standalone September 2019 Net Sales at Rs 3,370.18 crore, up 8.9% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-september-2019-net-sales-at-rs-3370-18-crore-up-8-9-y-o-y-4614101.html
205,"Cipla Consolidated September 2019 Net Sales at Rs 4,395.78 crore, up 9.57% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-september-2019-net-sales-at-rs-4395-78-crore-up-9-57-y-o-y-4614171.html
206,How Cipla's Umang Vohra is trying to invigorate the 84 year old company,https://www.moneycontrol.com/news/business/how-ciplas-umang-vohra-is-trying-to-invigorate-the-84-yearold-company-4548411.html
207,Cipla shares gain after acquiring anti-infective drug Elores,https://www.moneycontrol.com/news/business/markets/cipla-shares-gain-after-acquiring-anti-infective-drug-elores-4547251.html
208,Cipla Q2 PAT seen up 17% YoY to Rs. 442.8 cr: Emkay,https://www.moneycontrol.com/news/business/earnings/cipla-q2-pat-seen-up-17-yoy-to-rs-442-8-cr-emkay-4531371.html
209,Cipla rebounds 4% as management alleviates concerns on Goa unit observations,https://www.moneycontrol.com/news/business/markets/cipla-rebounds-4-as-management-alleviates-concerns-on-goa-unit-observations-4524721.html
210,Morgan Stanley bullish on these 2 pharma stocks which could give 32-47% return,https://www.moneycontrol.com/news/business/markets/morgan-stanley-bullish-on-these-2-pharma-stocks-which-could-give-32-47-return-4518791.html
211,Cipla launches skin treatment drug in US,https://www.moneycontrol.com/news/business/cipla-launches-skin-treatment-drug-in-us-4476041.html
212,Cipla announces closure of USFDA inspection at Bengaluru facility,https://www.moneycontrol.com/news/business/companies/cipla-announces-closure-of-usfda-inspection-at-bengaluru-facility-4462441.html
213,Top 10 high-conviction buying ideas from brokerage firms in a volatile market,https://www.moneycontrol.com/news/business/markets/top-10-high-conviction-buying-ideas-from-brokerage-firms-in-a-volatile-market-4415871.html
214,Cipla shares fall 2% after Credit Suisse cuts target price,https://www.moneycontrol.com/news/business/markets/cipla-shares-fall-2-after-credit-suisse-cuts-target-price-4371391.html
215,"Cipla shareholders approve raising up to Rs 3,000 crore",https://www.moneycontrol.com/news/business/companies/cipla-shareholders-approve-raising-up-to-rs-3000-crore-4344691.html
216,Buy Cipla; target of Rs 650: Sharekhan,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-650-sharekhan-4313341.html
217,Hold Cipla; target of Rs 520: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-520-icici-direct-4320911.html
218,"Cipla says change in generic business, cut-offs in month-end sales impacted India business",https://www.moneycontrol.com/news/business/cipla-says-change-in-generic-business-cut-offs-in-month-end-sales-impacted-india-business-4309021.html
219,"Cipla falls 3% on muted Q1 results; CLSA downgrades to sell, slashes target price",https://www.moneycontrol.com/news/business/stocks/cipla-falls-3-on-muted-q1-results-clsa-downgrades-to-sell-slashes-target-price-4306971.html
220,Cipla's net profit muted at Rs 447.2 crore in Q1FY20,https://www.moneycontrol.com/news/business/earnings/ciplas-net-profit-muted-at-rs-447-2-crore-in-q1fy20-4303001.html
221,"Cipla Consolidated June 2019 Net Sales at Rs 3,989.02 crore, up 1.27% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-june-2019-net-sales-at-rs-3989-02-crore-up-1-27-y-o-y-4303911.html
222,"Cipla Standalone June 2019 Net Sales at Rs 3,229.33 crore, up 8.09% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-june-2019-net-sales-at-rs-3229-33-crore-up-8-09-y-o-y-4303881.html
223,"Cipla, Iceland's Alvotech ink pact to sell biosimilar Adalimumab in emerging markets",https://www.moneycontrol.com/news/business/cipla-icelands-alvotech-ink-pact-to-sell-biosimilar-adalimumab-in-emerging-markets-4257631.html
224,"Cipla seeks favourable policy for domestic pharma cos, ease of doing biz",https://www.moneycontrol.com/news/business/companies/cipla-seeks-favourable-policy-for-domestic-pharma-cos-ease-of-doing-biz-4256071.html
225,Cipla rallies 4% as US arm acquires rights of key anti-infective drug Zemdri,https://www.moneycontrol.com/news/business/markets/cipla-rallies-4-as-us-arm-acquires-rights-of-key-anti-infective-drug-zemdri-4246711.html
226,Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug,https://www.moneycontrol.com/news/business/companies/cipla-arm-invagen-pharma-gets-usfda-nod-for-neuropathic-pain-management-drug-4229761.html
227,Cipla gains on setting up joint venture in China,https://www.moneycontrol.com/news/business/markets/cipla-gains-on-setting-up-joint-venture-in-china-4209011.html
228,Cipla inks pact with Acebright Group to build respiratory biz in China,https://www.moneycontrol.com/news/business/companies/cipla-inks-pact-with-acebright-group-to-build-respiratory-biz-in-china-4208401.html
229,Cipla Q1 PAT seen up 4.1% YoY to Rs. 465.1 cr: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/earnings/cipla-q1-pat-seen-up-4-1-yoy-to-rs-465-1-cr-prabhudas-lilladher-4199511.html
230,Looking at continued growth across key markets in FY20: Cipla,https://www.moneycontrol.com/news/business/companies/looking-at-continued-growth-across-key-markets-in-fy20-cipla-4021211.html
231,Cipla banks on limited competition launches to drive growth in US,https://www.moneycontrol.com/news/business/cipla-banks-on-limited-competition-launches-to-drive-growth-in-us-4007541.html
232,"Cipla Consolidated March 2019 Net Sales at Rs 4,403.98 crore, up 19.09% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-march-2019-net-sales-at-rs-4403-98-crore-up-19-09-y-o-y-4005821.html
233,"Cipla Standalone March 2019 Net Sales at Rs 3,456.53 crore, up 26.83% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-march-2019-net-sales-at-rs-3456-53-crore-up-26-83-y-o-y-4005811.html
234,Cipla Q4 net profit jumps 133% at Rs 357.68 crore,https://www.moneycontrol.com/news/business/earnings/cipla-q4-net-profit-jumps-133-at-rs-357-68-crore-4004771.html
235,USFDA inspection at Indore facility ends with zero observations: Cipla,https://www.moneycontrol.com/news/business/usfda-inspection-at-indore-facility-ends-with-zero-observations-cipla-3989011.html
236,Cash Market | A good risk reward trade in Cipla,https://www.moneycontrol.com/news/business/markets/cash-market-a-good-risk-reward-trade-in-cipla-3948821.html
237,"'Short-term traders can sell Nifty below 11,630 with stop loss at 11,700'",https://www.moneycontrol.com/news/business/markets/short-term-traders-can-sell-nifty-below-11630-keeping-a-tight-stop-loss-at-11700-3934901.html
238,Cipla gets USFDA nod for pulmonary arterial hypertension drug,https://www.moneycontrol.com/news/business/companies/cipla-gets-usfda-nod-for-pulmonary-arterial-hypertension-drug-3913101.html
239,"Dr Reddy's Laboratories, Cipla arm recall drugs in US market",https://www.moneycontrol.com/news/business/companies/dr-reddys-laboratories-cipla-arm-recall-drugs-in-us-market-3905051.html
240,Cipla Q4 PAT seen up 93.2% YoY to Rs. 295.8 cr: Kotak,https://www.moneycontrol.com/news/business/earnings/cipla-q4-pat-seen-up-93-2-yoy-to-rs-295-8-cr-kotak-3844181.html
241,"Cipla, Pulmatrix join hands to co-develop asthma drug",https://www.moneycontrol.com/news/business/cipla-pulmatrix-join-hands-to-co-develop-asthma-drug-3832111.html
242,Cipla Q4 PAT seen up 58.5% YoY to Rs. 283.1 cr: Prabhudas Lilladher,https://www.moneycontrol.com/news/business/earnings/cipla-q4-pat-seen-up-58-5-yoy-to-rs-283-1-cr-prabhudas-lilladher-3814711.html
243,Cipla launches Niveoli inhaler in India,https://www.moneycontrol.com/news/business/cipla-launches-niveoli-inhaler-in-india-3813541.html
244,"D-Street Buzz: Realty stocks shine led by Indiabulls Real Estate; Cipla jumps 2%, HDFC Bank most active",https://www.moneycontrol.com/news/business/markets/d-street-buzz-realty-stocks-shine-led-by-indiabulls-real-estate-cipla-jumps-2-hdfc-bank-most-active-3796921.html
245,"D-Street Buzz: Tata Steel, Cipla jump 3% each; DHFL extends gains, SBI drags",https://www.moneycontrol.com/news/business/markets/d-street-buzz-tata-steel-cipla-jump-3-each-dhfl-extends-gains-sbi-drags-3770221.html
246,Cipla signs $22 mn pact with Pulmatrix Inc for new asthma drug,https://www.moneycontrol.com/news/business/cipla-signs-22-mn-pact-with-pulmatrix-inc-for-new-asthma-drug-3742751.html
247,Cipla falls 2% on 8 GMP observations for Kurkumbh plant,https://www.moneycontrol.com/news/business/markets/cipla-falls-2-on-8-gmp-observations-for-kurkumbh-plant-3737561.html
248,Cipla gets 8 GMP observations from USFDA for Kurkumbh plant,https://www.moneycontrol.com/news/business/markets/cipla-gets-8-gmp-observations-from-usfda-for-kurkumbh-plant-3735011.html
249,Comment | Cipla takes a calculated risk with generic Sensipar launch,https://www.moneycontrol.com/news/opinion/comment-cipla-takes-a-calculated-risk-with-generic-sensipar-launch-3620571.html
250,India requires pragmatic compulsive licensing system: Cipla,https://www.moneycontrol.com/news/business/india-requires-pragmatic-compulsive-licensing-system-cipla-3616101.html
251,Cipla to launch cinacalcet hydrochloride tablets in US,https://www.moneycontrol.com/news/business/cipla-to-launch-cinacalcet-hydrochloride-tablets-in-us-3612901.html
252,Cipla to acquire 11.71% stake in Wellthy Therapeutics,https://www.moneycontrol.com/news/business/cipla-to-acquire-11-71-stake-in-wellthy-therapeutics-3555071.html
253,Buy Cipla; target of Rs 605: HDFC Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-605-hdfc-securities-2-3535991.html
254,Hold Cipla; target of Rs 545: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-545-icici-direct-3514011.html
255,Growth on topline has to improve: Cipla CEO Umang Vohra,https://www.moneycontrol.com/news/business/growth-on-topline-has-to-improve-cipla-ceo-umang-vohra-3497431.html
256,Cipla gets final approval for generic version of Adcirca,https://www.moneycontrol.com/news/business/cipla-gets-final-approval-for-generic-version-of-adcirca-3497731.html
257,"Cipla Consolidated December 2018 Net Sales at Rs 4,007.54 crore, up 2.39% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-december-2018-net-sales-at-rs-4007-54-crore-up-2-39-y-o-y-3493341.html
258,"Cipla Standalone December 2018 Net Sales at Rs 2,835.20 crore, down 4.54% Y-o-Y",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-december-2018-net-sales-at-rs-2835-20-crore-down-4-54-y-o-y-3493031.html
259,Cipla Q3 preview: Brokerages say firm facing global challenges; muted performance likely,https://www.moneycontrol.com/news/business/earnings/cipla-q3-preview-brokerages-say-company-facing-global-challenges-muted-performance-likely-3487631.html
260,Cipla Q3 PAT may dip 14% YoY to Rs. 405 cr: Sharekhan,https://www.moneycontrol.com/news/business/earnings/cipla-q3-pat-may-dip-14-yoy-to-rs-405-cr-sharekhan-3407391.html
261,Cipla Q3 PAT may dip 27.6% YoY to Rs. 290.1 cr: ICICI Direct,https://www.moneycontrol.com/news/business/earnings/cipla-q3-pat-may-dip-27-6-yoy-to-rs-290-1-cr-icici-direct-3380691.html
262,"Cadila, Cipla shares gain after HSBC upgrades to buy",https://www.moneycontrol.com/news/business/markets/cadila-cipla-shares-gain-after-hsbc-upgrades-to-buy-3359891.html
263,Transcript| Cipla Q2 FY19 Earnings Conference Call,https://www.moneycontrol.com/news/business/transcript-cipla-q2-fy19-earnings-conference-call-3342681.html
264,A look at how Cipla is trying to consolidate its position in respiratory segment,https://www.moneycontrol.com/news/business/companies/a-look-at-how-cipla-is-trying-to-consolidate-its-position-in-respiratory-segment-3334721.html
265,Buy Cipla; target of Rs 605: HDFC Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-605-hdfc-securities-3325681.html
266,Nifty likely to see profit booking after rally; these 3 stocks could return 6-8%,https://www.moneycontrol.com/news/business/markets/nifty-likely-to-see-profit-booking-after-rally-these-3-stocks-could-return-6-8-3244151.html
267,Pharma stocks poised for a bounceback; 3 bets for over 20% returns,https://www.moneycontrol.com/news/business/markets/pharma-stocks-poised-for-a-bounceback-3-bets-for-over-20-returns-3242251.html
268,Earnings estimates show Nifty could touch 12K by FY20; 15 stocks to watch,https://www.moneycontrol.com/news/business/markets/earnings-estimates-show-nifty-could-touch-12k-by-fy20-15-stocks-to-watch-3217051.html
269,Hold Cipla; target of Rs 510: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-510-icici-direct-3168761.html
270,Cipla's subsidiary to acquire US-based Avenue Therapeutics for $215 mn,https://www.moneycontrol.com/news/business/ciplas-subsidiary-to-acquire-us-based-avenue-therapeutics-for-215-mn-3159001.html
271,Top 12 growth stocks with strong management you can bet on for 1 year,https://www.moneycontrol.com/news/business/markets/top-12-growth-stocks-with-strong-management-you-can-bet-on-for-1-year-3148861.html
272,Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-anti-viral-eye-infection-drug-for-aids-patients-3148681.html
273,Market Headstart: Nifty likely to open flat; 3 stocks which could give 3-5% return,https://www.moneycontrol.com/news/business/markets/market-headstart-nifty-likely-to-open-flat-3-stocks-which-could-give-3-5-return-2-3148311.html
274,Interview: How Cipla plans to bounce back after a weak Q2,https://www.moneycontrol.com/news/interview/interview-how-cipla-plans-to-bounce-back-after-a-weak-q2-3135711.html
275,Continue to see GST impact of restocking in India sales: Cipla,https://www.moneycontrol.com/news/business/continue-to-see-gst-impact-of-restocking-in-india-sales-cipla-3136091.html
276,"Cipla down 5% on poor Q2, tough guidance ahead; Citi, HSBC downgrade ratings",https://www.moneycontrol.com/news/business/markets/cipla-down-5-on-poor-q2-tough-guidance-ahead-citi-hsbc-downgrade-ratings-3134641.html
277,"Cipla Consolidated September 2018 Net Sales at Rs 4,011.90 crore, Down 1.73% Q-o-Q.",https://www.moneycontrol.com/news/business/earnings/cipla-consolidated-september-2018-net-sales-at-rs-4011-90-crore-down-1-73-q-o-q-3131651.html
278,"Cipla Standalone September 2018 Net Sales at Rs 3,094.71 crore, up 0.96% Q-o-Q",https://www.moneycontrol.com/news/business/earnings/cipla-standalone-september-2018-net-sales-at-rs-3094-71-crore-up-0-96-q-o-q-3131041.html
279,Cipla Q2 profit falls 11% YoY at Rs 377 crore; posts weak operational show,https://www.moneycontrol.com/news/business/earnings/cipla-q2-profit-falls-11-yoy-at-rs-377-crore-posts-weak-operational-show-3130921.html
280,Promoters raise stake in 74 companies from BSE 500; does it make them attractive?,https://www.moneycontrol.com/news/business/markets/promoters-raise-stake-in-74-companies-from-bse-500-does-it-make-them-attractive-3117681.html
281,"Cipla gets USFDA nod for hypertension, cardiac drug",https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-hypertension-cardiac-drug-3097981.html
282,Cipla's arm completes acquisition of South Africa's Mirren,https://www.moneycontrol.com/news/business/ciplas-arm-completes-acquisition-of-south-africas-mirren-3075521.html
283,Hunting for value? These 10 expert picks are a buy after recent fall,https://www.moneycontrol.com/news/business/stocks/hunting-for-value-these-10-expert-picks-are-a-buy-after-recent-fall-3071661.html
284,"FII View | Foreign investors cautious on India, pharma & consumption attractive: Steven Birch",https://www.moneycontrol.com/news/business/markets/fii-view-foreign-investors-cautious-on-india-pharma-consumption-attractive-steven-birch-3062721.html
285,Cipla Q2 PAT may dip 6.7% YoY to Rs. 390 cr: HDFC Securities,https://www.moneycontrol.com/news/business/earnings/cipla-q2-pat-may-dip-6-7-yoy-to-rs-390-cr-hdfc-securities-3056901.html
286,Cipla Q2 PAT seen up 3% YoY to Rs. 450.4 cr: Sharekhan,https://www.moneycontrol.com/news/business/earnings/cipla-q2-pat-seen-up-3-yoy-to-rs-450-4-cr-sharekhan-3052711.html
287,Cipla Q2 PAT may dip 12.7% YoY to Rs. 368.9 cr: ICICI Direct,https://www.moneycontrol.com/news/business/earnings/cipla-q2-pat-may-dip-12-7-yoy-to-rs-368-9-cr-icici-direct-3039841.html
288,Market Headstart: Nifty likely to open flat; 3 stocks which could give 14-17% return,https://www.moneycontrol.com/news/business/markets/market-headstart-nifty-likely-to-open-flat-3-stocks-which-could-give-14-17-return-3021691.html
289,Podcast | Stock picks of the day: Cipla among 3 stocks which could return 14-17%,https://www.moneycontrol.com/news/business/stocks/podcast-stock-picks-of-the-day-cipla-among-3-stocks-which-could-return-14-17-3021621.html
290,Cipla stock gains nearly 2% on USFDA approval for anti-nausea drug,https://www.moneycontrol.com/news/business/markets/cipla-stock-gains-nearly-2-on-usfda-approval-for-anti-nausea-drug-2972371.html
291,Ugandan unit of Cipla raises $41 million in IPO: Broker,https://www.moneycontrol.com/news/business/markets/ugandan-unit-of-cipla-raises-41-million-in-ipo-broker-2959271.html
292,Cipla gets South African regulator's approval for new HIV drug,https://www.moneycontrol.com/news/business/cipla-gets-south-african-regulators-approval-for-new-hiv-drug-2943101.html
293,Buy Cipla; target of Rs 750: Centrum,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-750-centrum-2838301.html
294,Cipla arm secures marketing rights for cancer drug in US,https://www.moneycontrol.com/news/business/cipla-arm-secures-marketing-rights-for-cancer-drug-in-us-2832861.html
295,Cipla shares jump 5% post Q1 earnings,https://www.moneycontrol.com/news/business/earnings/cipla-shares-jump-5-post-q1-earnings-2824951.html
296,"Cipla Q1 preview: May deliver strong Q1 show on better sales in US, India and South Africa",https://www.moneycontrol.com/news/business/companies/cipla-q1-preview-may-deliver-strong-q1-show-on-better-sales-in-us-india-and-south-africa-2818491.html
297,Cipla gets USFDA nod for osteoarthritis of joint pain relief gel,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-osteoarthritis-of-joint-pain-relief-gel-2813261.html
298,Cipla Q1 PAT may dip 21.3% YoY to Rs. 321.8 cr: Kotak,https://www.moneycontrol.com/news/business/earnings/cipla-q1-pat-may-dip-21-3-yoy-to-rs-321-8-cr-kotak-2729171.html
299,Cipla's subsidiary to buy South Africa's Mirren South African Rand 450 mn,https://www.moneycontrol.com/news/business/ciplas-subsidiary-to-buy-south-africas-mirren-south-african-rand-450-mn-2701651.html
300,Cipla gets USFDA nod for generic Testosterone Cypionate injection,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-generic-testosterone-cypionate-injection-2616831.html
301,Cipla gets United States Food and Drug Administration nod for generic HIV drug,https://www.moneycontrol.com/news/business/cipla-gets-united-states-food-and-drug-administration-nod-for-generic-hiv-drug-2608261.html
302,Sensex rejig to take place on Monday; Motilal Oswal expects upgrade in combined EPS,https://www.moneycontrol.com/news/business/markets/sensex-rejig-to-take-place-on-monday-motilal-oswal-expects-upgrade-in-combined-eps-2596171.html
303,Cipla gets USFDA nod for generic Isuprel injection,https://www.moneycontrol.com/news/trends/health-trends/cipla-gets-usfda-nod-for-generic-isuprel-injection-2590125.html
304,Cipla partners with Eli Lilly to market diabetes drug Basaglar in India,https://www.moneycontrol.com/news/business/cipla-partners-with-eli-lilly-to-market-diabetes-drug-basaglar-in-india-2585923.html
305,Accumulate Cipla; target of Rs 585: Dolat Capital,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-target-of-rs-585-dolat-capital-2579807.html
306,Hold Cipla; target of Rs 530: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-530-icici-direct-2578883.html
307,Buy Cipla; target of Rs 600: JM Financial,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-600-jm-financial-2577155.html
308,Buy L&T Tech Services; target of Rs 1440: JM Financial,https://www.moneycontrol.com/news/business/stocks/buy-l-target-of-rs-1440-jm-financial-2577165.html
309,Accumulate Cipla; target of Rs 607: KR Choksey,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-target-of-rs-607-kr-choksey-2575953.html
310,Cipla shares gain 7% after March quarter earnings; analysts cut EPS estimates,https://www.moneycontrol.com/news/business/stocks/cipla-shares-gain-7-after-march-quarter-earnings-analysts-cut-eps-estimates-2573927.html
311,Cipla Q4 profit at Rs 153 cr versus loss last year; misses estimates,https://www.moneycontrol.com/news/business/earnings/cipla-q4-profit-at-rs-153-cr-versus-loss-last-year-misses-estimates-2573323.html
312,Q4 preview: Cipla to be back in black on improved sales from India and South Africa,https://www.moneycontrol.com/news/business/earnings/q4-preview-cipla-to-be-back-in-black-on-improved-sales-from-india-and-south-africa-2573195.html
313,Stempeutics partners with Cipla for its stem cell drug,https://www.moneycontrol.com/news/business/stempeutics-partners-with-cipla-for-its-stem-cell-drug-2571179.html
314,"Stay cautious, Nifty likely to struggle around 10,780 levels; Short Cipla",https://www.moneycontrol.com/news/business/stay-cautious-nifty-likely-to-struggle-around-10780-levels-short-cipla-2566679.html
315,Cipla enters into exclusive pact with US-based MannKind to sell inhaled insulin in India,https://www.moneycontrol.com/news/business/companies/cipla-enters-into-exclusive-pact-with-us-based-mannkind-to-sell-inhaled-insulin-in-india-2565741.html
316,"Market Update: CNX Pharma falls 1% dragged by Aurobindo Pharma, GAIL, ONGC top losers; Airtel top gainer",https://www.moneycontrol.com/news/business/market-update-cnx-pharma-falls-1-dragged-by-aurobindo-pharma-gail-ongc-top-losers-airtel-top-gainer-2556893.html
317,"Market Update: IT, Realty sectors in green despite Nifty in red; TCS, Airtel up 2-4%, M&M at 52-week high",https://www.moneycontrol.com/news/business/market-update-it-realty-sectors-in-green-despite-nifty-in-red-tcs-airtel-up-2-4-mm-at-52-week-high-2556731.html
318,"Market Update: Nifty Pharma gains led by Cipla,  Divi's Labs; Zee Entertainment up 2%, DHFL most active",https://www.moneycontrol.com/news/business/market-update-nifty-pharma-gains-led-by-cipla-divis-labs-zee-entertainment-up-2-dhfl-most-active-2551151.html
319,Cipla may test Rs 650 on robust Q4FY18 results: Akash Jain,https://www.moneycontrol.com/news/business/cipla-may-test-rs-650-on-robust-q4fy18-results-akash-jain-2550533.html
320,"Buy Cipla, target Rs 650: S Ranganathan",https://www.moneycontrol.com/news/business/buy-cipla-target-rs-650-s-ranganathan-2550461.html
321,USFDA conducts inspection at Cipla's Indore facility,https://www.moneycontrol.com/news/business/usfda-conducts-inspection-at-ciplas-indore-facility-2550179.html
322,Cipla Q4 PAT seen up 57.7% YoY to Rs. 322 cr: Edelweiss,https://www.moneycontrol.com/news/business/earnings/cipla-q4-pat-seen-up-57-7-yoy-to-rs-322-cr-edelweiss-2549911.html
323,"Market Update: Sensex, Nifty rebound as realty stocks outperform; HDFC Bank up 1%; Cipla top Nifty gainer",https://www.moneycontrol.com/news/business/market-update-sensex-nifty-rebound-as-realty-stocks-outperform-hdfc-bank-up-1-cipla-top-nifty-gainer-2549867.html
324,Cipla gains 5% after USFDA inspection with no data integrity or repeat observations,https://www.moneycontrol.com/news/business/stocks/cipla-gains-5-after-usfda-inspection-with-no-data-integrity-or-repeat-observations-2549733.html
325,"Market Update: Cipla, Lupin jump 5% as CNX Pharma gains 2%; Avenue Supermarts hits new 52-week high, ICICI most active",https://www.moneycontrol.com/news/business/market-update-cnx-pharma-up-2-led-by-cipla-lupin-psu-bank-index-drags-icici-bank-tanks-6-2540705.html
326,From Sun to Cipla - Biggest M&As in the Indian pharma industry that made profits or bombed,https://www.moneycontrol.com/news/photos/business/companies/from-sun-to-cipla-biggest-mas-in-the-indian-pharma-industry-that-made-profits-or-bombed-2537993.html
327,Cipla gets USFDA observations for its Goa plant,https://www.moneycontrol.com/news/business/cipla-gets-usfda-observations-for-its-goa-plant-2532717.html
328,Cipla shares trim losses after company clarifies on USFDA observations for Goa unit,https://www.moneycontrol.com/news/business/stocks/cipla-shares-trim-losses-after-company-clarifies-on-usfda-observations-for-goa-unit-2532039.html
329,"Cipla to distribute Roche's tocilizumab, bevacizumab in India",https://www.moneycontrol.com/news/business/companies/cipla-to-distribute-roches-biologics-tocilizumab-and-bevacizumab-in-india-2517611.html
330,Hold Cipla; target of Rs 653: Geojit,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-653-geojit-2517047.html
331,"Buy Bata India, Cipla, Hindustan Unilever, Tata Elxsi; sell Bharti Airtel: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/buy-bata-india-cipla-hindustan-unilever-tata-elxsi-sell-bharti-airtel-sudarshan-sukhani-2505669.html
332,Buy Cipla; target of Rs 714: KR Choksey,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-714-kr-choksey-2508055.html
333,"Buy Gujarat Alkalies, GNFC, Cipla: Rajat Bose",https://www.moneycontrol.com/news/business/buy-gujarat-alkalies-gnfc-cipla-rajat-bose-2502901.html
334,"Cipla rallies 7% as global analysts remain positive post Q3 earnings, management commentary",https://www.moneycontrol.com/news/business/stocks/cipla-rallies-7-as-global-analysts-remain-positive-post-q3-earnings-management-commentary-2502885.html
335,"Market Update: CNX Realty up 2% as Sensex, Nifty gain; Ashok Leyland hits 52-week high, HEG zooms 11%",https://www.moneycontrol.com/news/business/market-update-cnx-realty-up-2-as-sensex-nifty-gains-ashok-leyland-hits-52-week-high-heg-zooms-11-2502793.html
336,"Cipla Q3 profit grows 5% on better operational show, tax reversal",https://www.moneycontrol.com/news/business/earnings/cipla-q3-profit-grows-5-on-better-operational-show-tax-reversal-2502041.html
337,"Cipla Q3 profit seen up 13%; generic Renvela, Pulmicort, Dacogen may drive US biz",https://www.moneycontrol.com/news/business/earnings/cipla-q3-profit-seen-up-13-generic-renvela-pulmicort-dacogen-may-drive-us-biz-2501927.html
338,Cipla gets USFDA approval for HIV drug,https://www.moneycontrol.com/news/business/cipla-gets-usfda-approval-for-hiv-drug-2493317.html
339,"Buy Cipla, IndusInd Bank, Maruti Suzuki, Apollo Tyres; sell India Cements: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/buy-cipla-indusind-bank-maruti-suzuki-apollo-tyres-sell-india-cements-sudarshan-sukhani-2490961.html
340,"Market Update: L&T, ONGC, Vedanta hit record highs despite broader indices trading flat; SBI falls 2%",https://www.moneycontrol.com/news/business/market-update-l-sbi-falls-2-2490821.html
341,"Buy Cipla, DLF, Sun TV Network, ITC; exit Apex Frozen Foods: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/buy-cipla-dlf-sun-tv-network-itc-exit-apex-frozen-foods-sudarshan-sukhani-2488903.html
342,"Buy Ashok Leyland, NMDC, JSW Steel: Ashwani Gujral",https://www.moneycontrol.com/news/business/buy-ashok-leyland-nmdc-jsw-steel-ashwani-gujral-2488929.html
343,Cipla gets WHO nod to sell TB preventing drug in HIV patients,https://www.moneycontrol.com/news/business/cipla-gets-who-nod-to-sell-tb-preventing-drug-in-hiv-patients-2451013.html
344,Cipla Health to expand consumer health biz with new launches and acquisitions,https://www.moneycontrol.com/news/business/companies/cipla-health-to-expand-consumer-health-biz-with-new-launches-and-acquisitions-2450317.html
345,Cipla's generic Dacogen gets USFDA go-ahead,https://www.moneycontrol.com/news/business/ciplas-generic-dacogen-gets-usfda-go-ahead-2442367.html
346,Weekly wrap: Pharma stocks end Nov 13-17 week in red as Q2 results fail to spur investor interest,https://www.moneycontrol.com/news/business/weekly-wrap-pharma-stocks-end-nov-13-17-week-in-red-as-q2-results-fail-to-spur-investor-interest-2442009.html
347,"IndusInd Bank, Yes Bank to join BSE Sensex; Cipla, Lupin exit",https://www.moneycontrol.com/news/business/markets/indusind-bank-yes-bank-to-join-bse-sensex-cipla-lupin-exit-2441791.html
348,See limited competition for Pulmicort; expect 3-4 more approvals by FY18-end: Cipla,https://www.moneycontrol.com/news/business/companies/see-limited-competition-for-pulmicort-expect-3-4-more-approvals-by-fy18-end-cipla-2441291.html
349,USFDA gives final approval to Cipla's anti-asthma product,https://www.moneycontrol.com/news/business/usfda-gives-final-approval-to-ciplas-anti-asthma-product-2441157.html
350,Buy Cipla; target of Rs 700: Centrum,https://www.moneycontrol.com/news/business/stocks/buy-cipla-target-of-rs-700-centrum-2440397.html
351,Cipla plans to enter China's branded respiratory business in coming quarters,https://www.moneycontrol.com/news/business/companies/cipla-plans-to-enter-chinas-branded-respiratory-business-in-coming-quarters-2433409.html
352,"Cipla Q2 beats estimates, profit rises 18% to Rs 435 cr on operational performance",https://www.moneycontrol.com/news/business/earnings/cipla-q2-beats-estimates-profit-rises-18-to-rs-435-cr-on-operational-performance-2431849.html
353,Cipla Q2 profit seen up 17%; export formulations business may grow around 10%,https://www.moneycontrol.com/news/business/earnings/cipla-q2-profit-seen-up-17-export-formulations-business-may-grow-around-10-2431395.html
354,Cipla gets USFDA nod for generic version of Renvela tablets,https://www.moneycontrol.com/news/business/cipla-gets-usfda-nod-for-generic-version-of-renvela-tablets-2421409.html
355,Cipla Q2 PAT seen up 13% YoY to Rs. 406 cr: Kotak,https://www.moneycontrol.com/news/business/stocks/cipla-q2-pat-seen-up-13-yoy-to-rs-406-cr-kotak-2412425.html
356,"Buy Sun Pharma, Escorts; sell Indiabulls Real Estate, United Spirits: Thakkar",https://www.moneycontrol.com/news/business/buy-sun-pharma-escorts-sell-indiabulls-real-estate-united-spirits-thakkar-2407915.html
357,"Market Now: Jewellery stocks shine - PC Jeweller, Titan up 3-4%; ICICI Bank top gainer",https://www.moneycontrol.com/news/business/market-now-jewellery-stocks-shine-pc-jeweller-titan-up-3-4-icici-bank-top-gainer-2407813.html
358,"Buy Kotak Mahindra Bank, Cipla; sell SREI Infrastructure: Ashwani Gujral",https://www.moneycontrol.com/news/business/buy-kotak-mahindra-bank-cipla-sell-srei-infrastructure-ashwani-gujral-2394837.html
359,"Buy Cipla, sell DLF; hold Piramal Enterprises, CRISIL: Sandeep Wagle",https://www.moneycontrol.com/news/business/buy-cipla-sell-dlf-hold-piramal-enterprises-crisil-sandeep-wagle-2394697.html
360,"Buy Glenmark Pharma, Ajanta Pharma, Cipla: Ashwani Gujral",https://www.moneycontrol.com/news/business/buy-glenmark-pharma-ajanta-pharma-cipla-ashwani-gujral-2393863.html
361,"Buy Cipla, sell Reliance Capital: Rajat Bose",https://www.moneycontrol.com/news/business/buy-cipla-sell-reliance-capital-rajat-bose-2393807.html
362,"Buy Novartis, Cipla, Bajaj Auto, Rain Industries: Rajat Bose",https://www.moneycontrol.com/news/business/buy-novartis-cipla-bajaj-auto-rain-industries-rajat-bose-2393615.html
363,"Buy Cipla, Coal India: Mitessh Thakkar",https://www.moneycontrol.com/news/business/buy-cipla-coal-india-mitessh-thakkar-2390689.html
364,New draft pharma policy will reduce risks like generalisation of mkt: JM Financial,https://www.moneycontrol.com/news/business/companies/new-draft-pharma-policy-will-reduce-risks-like-generalisation-of-mkt-jm-financial-2389033.html
365,"Buy Cipla, Tata Elxsi, ACC: Rajat Bose",https://www.moneycontrol.com/news/business/buy-cipla-tata-elxsi-acc-rajat-bose-2385477.html
366,"Cipla promoters, relatives get into share transfer agreement",https://www.moneycontrol.com/news/business/cipla-promoters-relatives-get-into-share-transfer-agreement-2380999.html
367,"Buy Cipla, Oil India, Petronet LNG; sell Larsen & Toubro, Raymond: Mitessh Thakkar",https://www.moneycontrol.com/news/business/buy-cipla-oil-india-petronet-lng-sell-larsen-toubro-raymond-mitessh-thakkar-2362203.html
368,Hold Cipla; target of Rs 525: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-525-icici-direct-2361099.html
369,"Buy Cipla, Indusind Bank: Mitessh Thakkar",https://www.moneycontrol.com/news/business/buy-cipla-indusind-bank-mitessh-thakkar-2361307.html
370,Cipla jumps 6% after management's FY18 outlook; analysts retain hold rating,https://www.moneycontrol.com/news/business/earnings/cipla-jumps-6-after-managements-fy18-outlook-analysts-retain-hold-rating-2359683.html
371,"Crucial support for Nifty at 9700; buy Aurobindo Pharma, sell Vedanta: Prakash Gaba",https://www.moneycontrol.com/news/business/crucial-support-for-nifty-at-9700-buy-aurobindo-pharma-sell-vedanta-prakash-gaba-2358745.html
372,Pharma weekly wrap: Pharma stocks had tough week due to GST and pricing pressures in US,https://www.moneycontrol.com/news/business/pharma-weekly-wrap-pharma-stocks-had-tough-week-due-to-gst-and-pricing-pressures-in-us-2-2358411.html
373,Cipla hopes to generate sustainable top-line growth in FY18,https://www.moneycontrol.com/news/business/cipla-hopes-to-generate-sustainable-top-line-growth-in-fy18-2357987.html
374,"Cipla profit rises 21% to Rs 409 cr in Q1 on cost controls, operational efficiency",https://www.moneycontrol.com/news/business/earnings/cipla-profit-rises-21-to-rs-409-cr-in-q1-on-cost-controls-operational-efficiency-2357463.html
375,"Buy NMDC, Cipla: Hemant Thukral",https://www.moneycontrol.com/news/business/buy-nmdc-cipla-hemant-thukral-2354593.html
376,Nifty likely to find support near 9900; top 5 stocks which can give up to 15% return,https://www.moneycontrol.com/news/business/markets/nifty-likely-to-find-support-near-9900-top-5-stocks-which-can-give-up-to-15-return-2354413.html
377,Cipla eyes filing over 20 ANDAs in US this fiscal,https://www.moneycontrol.com/news/business/cipla-eyes-filing-over-20-andas-in-us-this-fiscal-2339649.html
378,"Buy V-guard Industries, Cipla, Larsen &amp; Toubro: Ashwani Gujral",https://www.moneycontrol.com/news/business/buy-v-guard-industries-cipla-larsen-toubro-ashwani-gujral-2336467.html
379,Cipla gains 1% after launching anti-malaria drug for young children,https://www.moneycontrol.com/news/business/stocks/cipla-gains-1-after-launching-anti-malaria-drug-for-young-children-2336181.html
380,"Stocks in the news: HDFC, Cipla, Yes Bank, Bharti Airtel, TD Power, PNB, Suzlon, National Fertilizers",https://www.moneycontrol.com/news/business/stocks/stocks-in-the-news-hdfc-cipla-yes-bank-bharti-airtel-td-power-pnb-suzlon-national-fertilizers-2335781.html
381,Cipla announces launch of anti-malaria drug in Sub-Saharan Africa,https://www.moneycontrol.com/news/business/cipla-announces-launch-of-anti-malaria-drug-in-sub-saharan-africa-2335695.html
382,"Buy Britannia Industries; sell UltraTech Cement, Jubilant Foodworks: Ashwani Gujral",https://www.moneycontrol.com/news/business/buy-britannia-industries-sell-ultratech-cement-jubilant-foodworks-ashwani-gujral-2329725.html
383,Cipla Q1 PAT may dip 46.52% YoY to Rs 199.6 cr: KR Choksey,https://www.moneycontrol.com/news/business/earnings/cipla-q1-pat-may-dip-427-75-to-rs-199-6-cr-kr-choksey-2328593.html
384,"Buy Bajaj Auto, Cipla, DLF; sell Tata Communications, Amara Raja: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/buy-bajaj-auto-cipla-dlf-sell-tata-communications-amara-raja-sudarshan-sukhani-2328253.html
385,Nifty faces profit booking; 5 stocks to buy today which can give decent gains,https://www.moneycontrol.com/news/business/stocks/nifty-faces-profit-booking-5-stocks-to-buy-today-which-can-give-decent-gains-2328203.html
386,"Resistance for Nifty at 9969; buy Apollo Tyres, Adani Ports, DHFL: Prakash Gaba",https://www.moneycontrol.com/news/business/resistance-for-nifty-at-9969-buy-apollo-tyres-adani-ports-dhfl-prakash-gaba-2328163.html
387,"Buy Maruti, Eicher, Cipla, Gujarat Alkalies, Tata Chem, United Spirits: HDFC Sec",https://www.moneycontrol.com/news/business/buy-maruti-eicher-cipla-gujarat-alkalies-tata-chem-united-spirits-hdfc-sec-2316891.html
388,"Cautious on Nifty, key support at 9451; 4 stocks to buy or sell today: Prakash Gaba",https://www.moneycontrol.com/news/business/cautious-on-nifty-key-support-at-9451-4-stocks-to-buy-or-sell-today-prakash-gaba-2313257.html
389,"Bull's Eye: Buy Cipla, Reliance Defence, Century Textiles, Mindtree; Sell Sun TV",https://www.moneycontrol.com/news/business/stocks/bulls-eye-buy-cipla-reliance-defence-century-textiles-mindtree-sell-sun-tv-2312215.html
390,Cipla settles patent infringement case with Roche over cancer drug Tarceva,https://www.moneycontrol.com/news/business/companies/cipla-settles-patent-infringement-case-with-roche-over-cancer-drug-tarceva-2310223.html
391,"Sell Cipla, Biocon; buy VRL Logistics: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/sell-cipla-biocon-buy-vrl-logistics-ashwani-gujral-2307213.html
392,"Buy ITC, Federal Bank, Bharat Forge: Yogesh Mehta",https://www.moneycontrol.com/news/business/stocks/buy-itc-federal-bank-bharat-forge-yogesh-mehta-2307061.html
393,Cancer drug: SC allows Cipla to withdraw appeal against Roche,https://www.moneycontrol.com/news/business/cancer-drug-sc-allows-cipla-to-withdraw-appeal-against-roche-2306041.html
394,Top 5 stocks which could give up to 13% return in short term,https://www.moneycontrol.com/news/business/markets/top-5-stocks-which-could-give-up-to-13-return-in-short-term-2304503.html
395,Dr Reddy's recalls 3.25L cartons Cipla-made acne drug from US,https://www.moneycontrol.com/news/business/dr-reddys-recalls-3-25l-cartons-cipla-made-acne-drug-from-us-2303995.html
396,Nifty may face resistance at 9724; 4 stocks to bet on today,https://www.moneycontrol.com/news/business/nifty-may-face-resistance-at-9724-4-stocks-to-bet-on-today-2300613.html
397,Hold Cipla; target of Rs 470: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-470-icici-direct-2291665.html
398,Hold Cipla; target of Rs 510: Edelweiss,https://www.moneycontrol.com/news/business/stocks/hold-cipla-target-of-rs-510-edelweiss-2289961.html
399,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/six-in-sixty-stocks-you-should-keep-on-your-radar-45-2290035.html
400,CLSA downgrades Cipla to underperform post Q4; cuts target price to Rs 525,https://www.moneycontrol.com/news/business/stocks/clsa-downgrades-cipla-to-underperform-post-q4-cuts-target-price-to-rs525-2289505.html
401,Cipla puts biosimilar business on backburner as part of business rationalisation,https://www.moneycontrol.com/news/business/companies/cipla-puts-biosimilar-business-on-backburner-as-part-of-business-rationalisation-2289369.html
402,Cipla’s post Q4 net loss of Rs 61.8 cr; depreciation & impairment weigh in on financials,https://www.moneycontrol.com/news/business/earnings/ciplas-post-q4-net-loss-of-rs-61-8-cr-depreciation-impairment-weigh-in-on-financials-2289081.html
403,"Hold Cipla, may test Rs 600: Rajesh Agarwal",https://www.moneycontrol.com/news/business/stocks/hold-cipla-may-test-rs-600-rajesh-agarwal-2288965.html
404,"Buy Cipla at around Rs 400, says Rajat Bose",https://www.moneycontrol.com/news/business/stocks/buy-cipla-at-around-rs-400-says-rajat-bose-2288951.html
405,"Cipla Q4: Net profit seen at Rs 346.8 crore, revenues could rise to Rs 3,790 crore: Poll",https://www.moneycontrol.com/news/business/earnings/cipla-q4-net-profit-seen-at-rs-346-8-crore-revenues-could-rise-to-rs-3790-crore-poll-2287971.html
406,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/six-in-sixty-stocks-you-should-keep-on-your-radar-44-2287739.html
407,Why did pharmaceutical stocks take a hit today?,https://www.moneycontrol.com/news/business/stocks/why-are-pharmaceutical-stocks-taking-a-hit-today-2286583.html
408,"Sell Just Dial, Cipla: Mitessh Thakkar",https://www.moneycontrol.com/news/business/sell-just-dial-cipla-mitessh-thakkar-2286181.html
409,"Buy ITC, Petronet LNG, Cipla; sell BPCL: Chandan Taparia",https://www.moneycontrol.com/news/business/buy-itc-petronet-lng-cipla-sell-bpcl-chandan-taparia-2284911.html
410,"Bull's Eye: Buy Cipla, Eveready, Emami, Concor, Godrej, EIH, Fortis Health",https://www.moneycontrol.com/news/business/stocks/bulls-eye-buy-cipla-eveready-emami-concor-godrej-eih-fortis-health-2284783.html
411,Here's what happened in the pharma sector last week,https://www.moneycontrol.com/news/business/companies/heres-what-happened-in-the-pharma-sector-last-week-2284473.html
412,"Sell Cipla, buy Mangalore Refineries & Petrochemicals: Mitessh Thakkar",https://www.moneycontrol.com/news/business/sell-cipla-buy-mangalore-refineries-petrochemicals-mitessh-thakkar-2282467.html
413,"Sell Kaveri Seed, Colgate, Cipla; buy M&M, DCB Bank: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/sell-kaveri-seed-colgate-cipla-buy-mm-dcb-bank-sudarshan-sukhani-2282443.html
414,"Resistance for bank Nifty at 22850; Tech Mahindra, Cipla bullish plays: Prakash Gaba",https://www.moneycontrol.com/news/business/resistance-for-bank-nifty-at-22850-tech-mahindra-cipla-bullish-plays-prakash-gaba-2278733.html
415,Pharma: Here's what all happened in the sector last week,https://www.moneycontrol.com/news/business/companies/pharma-heres-what-all-happened-in-the-sector-last-week-2-2278433.html
416,"Cipla may test Rs 576, Rallis India Rs 260: Prakash Gaba",https://www.moneycontrol.com/news/business/cipla-may-test-rs-576-rallis-india-rs-260-prakash-gaba-2277429.html
417,"Buy Infosys, TCS, HCL Tech, IRB Infrastructure; sell Cipla: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/buy-infosys-tcs-hcl-tech-irb-infrastructure-sell-cipla-sudarshan-sukhani-2274105.html
418,Pharma: Here's what all happened in the sector last week,https://www.moneycontrol.com/news/uncategorized/pharma-heres-what-all-happened-in-the-sector-last-week-2268405.html
419,"Resistance for Bank Nifty at 22500; buy BEML, Cipla, Crisil: Prakash Gaba",https://www.moneycontrol.com/news/business/resistance-for-bank-nifty-at-22500-buy-beml-cipla-crisil-prakash-gaba-2266365.html
420,"Buy Colgate Palmolive, Coffee Day, MMTC, Rolta India; sell Cipla: Mitessh Thakkar",https://www.moneycontrol.com/news/business/buy-colgate-palmolive-coffee-day-mmtc-rolta-india-sell-cipla-mitessh-thakkar-2263991.html
421,Buy Shipping Corporation of India; sell Cipla: Mitessh Thakkar,https://www.moneycontrol.com/news/business/buy-shipping-corporation-of-india-sell-cipla-mitessh-thakkar-2263295.html
422,Buy M&amp;M Financial; sell Cipla; RIL may test Rs 2200 in 12-15 months: Wagle,https://www.moneycontrol.com/news/business/buy-mm-financial-sell-cipla-ril-may-test-rs-2200-in-12-15-months-wagle-2263017.html
423,Cipla Q4 PAT seen up 7.3% to Rs 326.3 cr: ICICI Securities,https://www.moneycontrol.com/news/business/cipla-q4-pat-seen-up-7-3-to-rs-326-3-cr-icici-securities-2258943.html
424,"Stocks in the news: IOC, Cipla, Nestle, Indian Hume Pipe, Reliance Power",https://www.moneycontrol.com/news/business/stocks/stocks-in-news-ioc-cipla-nestle-indian-hume-pipe-reliance-power-2258853.html
425,"Stocks in the news: Reliance, Infosys, Cipla, Arshiya, IOL Chem, Laurel, Majesco",https://www.moneycontrol.com/news/business/stocks/stocks-in-the-news-reliance-infosys-cipla-arshiya-iol-chem-laurel-majesco-2257705.html
426,Cipla arm completes acquisition of South Africa-based firm Anmarate,https://www.moneycontrol.com/news/business/cipla-arm-completes-acquisition-of-south-africa-based-firm-anmarate-2257635.html
427,Indian drug market grows at 9.6% in March on waning demonetisation effect,https://www.moneycontrol.com/news/trends/health-trends/indian-drug-market-grows-at-9-6-in-march-on-waning-demonetisation-effect-2257441.html
428,"Buy Canara Bank, IGL, Power Grid; sell Bharat Financial, Cipla: Mitessh Thakkar",https://www.moneycontrol.com/news/business/buy-canara-bank-igl-power-grid-sell-bharat-financial-cipla-mitessh-thakkar-2257103.html
429,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/six-in-sixty-stocks-you-should-keep-on-your-radar-19-2256763.html
430,Buy Engineers India; sell Cipla: Mitessh Thakkar,https://www.moneycontrol.com/news/business/buy-engineers-india-sell-cipla-mitessh-thakkar-2256737.html
431,"Stocks in the news: Cipla, HUL, Voltas, MEP Infra, GE Power, SMS Pharma, Deepak Fert",https://www.moneycontrol.com/news/business/stocks/stocks-in-the-news-cipla-hul-voltas-mep-infra-ge-power-sms-pharma-deepak-fert-2254401.html
432,Cipla's US arm inks licensing pact with MEDRx,https://www.moneycontrol.com/news/business/ciplas-us-arm-inks-licensing-pact-with-medrx-2254007.html
433,Cipla gets US FDA nod to sell generic HIV tablets,https://www.moneycontrol.com/news/business/companies/cipla-gets-us-fda-nod-to-sell-generic-hiv-tablets-2252385.html
434,Cipla acquires South Africa-based firm for ZAR 26 mn,https://www.moneycontrol.com/news/business/cipla-acquires-south-africa-based-firm-for-zar-26-mn-2251141.html
435,"Buy, Sell, Hold: 9 stocks, 1 sector on analysts' radar as April series begins",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-banks-pharma-and-fmcg-are-on-analysts-radar-today-2250283.html
436,"Prefer Cipla, Aurobindo Pharma: Gaurang Shah",https://www.moneycontrol.com/news/business/stocks/prefer-cipla-aurobindo-pharma-gaurang-shah-2-2247669.html
437,"Mkt to trade sideways; spaces like cement, auto ancillary, PSU banks look good: Pros",https://www.moneycontrol.com/news/business/markets/mkt-to-trade-sideways-spaces-like-cement-auto-ancillary-psu-banks-look-good-pros-2246853.html
438,Here’s why JPMorgan has a neutral rating on Cipla,https://www.moneycontrol.com/news/business/stocks/heres-why-jpmorgan-has-a-neutral-rating-on-cipla-2245735.html
439,"Buy, Sell, Hold: Which stocks are analysts tracking today?",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-which-stocks-are-analysts-tracking-today-2245295.html
440,"Buy Ceat, Cipla, Siemens, Ajanta Pharma, Ipca Labs: Mitessh Thakkar",https://www.moneycontrol.com/news/business/buy-ceat-cipla-siemens-ajanta-pharma-ipca-labs-mitessh-thakkar-2150747.html
441,"3 top picks from Reliance Securities: Pidilite, Cipla & IOC",https://www.moneycontrol.com/news/business/stocks/3-top-picks-from-reliance-securities-pidilite-cipla-ioc-2150017.html
442,Indian drug market growth moderates to 7.1% in February,https://www.moneycontrol.com/news/business/companies/indian-drug-market-growth-moderates-to-71february-1057269.html
443,"Divis Lab, Cipla, Strides Shasun to get astro support: Gupta",https://www.moneycontrol.com/news/business/markets/divis-lab-cipla-strides-shasun-to-get-astro-support-gupta-1057649.html
444,"Stocks in news: Cipla, Kotak Bank, Infosys, Wockhardt, Cadila",https://www.moneycontrol.com/news/business/stocks/stocksnews-cipla-kotak-bank-infosys-wockhardt-cadila-1057669.html
445,"Cipla gains 1%, to divest 100% stake in animal health business",https://www.moneycontrol.com/news/business/stocks/cipla-gains-1-to-divest-100-stakeanimal-health-business-1059115.html
446,"Stocks in news: Cipla, Bharat Forge, Shree Cement, SREI, AB Nuvo",https://www.moneycontrol.com/news/business/stocks/stocksnews-cipla-bharat-forge-shree-cement-srei-ab-nuvo-1059079.html
447,Cipla sells its animal health biz in South Africa and Sub-Sahara,https://www.moneycontrol.com/news/business/companies/cipla-sells-its-animal-health-bizsouth-africasub-sahara-1059345.html
448,Dr Reddy's is favourite hunting ground for Cipla's top talent,https://www.moneycontrol.com/news/business/companies/dr-reddys-is-favourite-hunting-ground-for-ciplas-top-talent-1059347.html
449,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-1060451.html
450,Cipla to remain unfazed by Trump's protectionist policy,https://www.moneycontrol.com/news/business/companies/cipla-to-remain-unfazed-by-trumps-protectionist-policy-1059395.html
451,Here are top trading ideas from Rahul Arora,https://www.moneycontrol.com/news/business/stocks/heretop-trading-ideasrahul-arora-1060439.html
452,Drug cos focus on automation & work culture to meet compliance,https://www.moneycontrol.com/news/business/companies/drug-cos-focusautomationwork-culture-to-meet-compliance-1034619.html
453,Pharma body comes up with new guidelines on data integrity,https://www.moneycontrol.com/news/business/companies/pharma-body-comes-upnew-guidelinesdata-integrity-1034918.html
454,634 drugs on NPPA's price ceiling non-compliant list,https://www.moneycontrol.com/news/business/companies/634-drugsnppas-price-ceiling-non-compliant-list-1034071.html
455,"Cipla to sell animal health biz soon;focus on China, Brazil mkts",https://www.moneycontrol.com/news/business/companies/cipla-to-sell-animal-health-biz-soonfocuschina-brazil-mkts-1034515.html
456,Here‘s why Deutsche Bank is upbeat on pharmaceutical sector,https://www.moneycontrol.com/news/business/stocks/hereâ€™sdeutsche-bank-is-upbeatpharmaceutical-sector-1032923.html
457,Compulsory licensing required for essential drugs: Y K Hamied,https://www.moneycontrol.com/news/business/companies/compulsory-licensing-required-for-essential-drugs-y-k-hamied-1015584.html
458,Telecom stocks very attractive from 3-year horizon: ICICI Pru,https://www.moneycontrol.com/news/business/markets/telecom-stocks-very-attractive3-year-horizon-icici-pru-1015160.html
459,"Cipla, Serum Institute launch Hepatitis B vaccine",https://www.moneycontrol.com/news/business/companies/cipla-serum-institute-launch-hepatitis-b-vaccine-1006213.html
460,"Stocks in news: SBI, TCS, Tata Steel, Cipla, SBT, SBBJ, Cyient",https://www.moneycontrol.com/news/business/stocks/stocksnews-sbi-tcs-tata-steel-cipla-sbt-sbbj-cyient-1003940.html
461,Buy Cipla; target of Rs 740: Centrum,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-740-centrum-1004056.html
462,Cipla joins the race to build specialty branded business in US,https://www.moneycontrol.com/news/business/companies/cipla-joinsrace-to-build-specialty-branded-businessus-1004724.html
463,Hold Cipla; target of Rs 575: ICICI Direct,https://www.moneycontrol.com/news/business/stocks/hold-cipla-targetrs-575-icici-direct-1005105.html
464,Buy Cipla; target of Rs 690: KR Choksey,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-690-kr-choksey-1005228.html
465,Hold Cipla; target of Rs 500: Edelweiss,https://www.moneycontrol.com/news/business/stocks/hold-cipla-targetrs-500-edelweiss-1005376.html
466,"Buy Adani Ports, Arvind; sell Cipla: Sandeep Wagle",https://www.moneycontrol.com/news/business/stocks/buy-adani-ports-arvind-sell-cipla-sandeep-wagle-1002286.html
467,"Hold Cipla, may test Rs 700: Vijay Chopra",https://www.moneycontrol.com/news/business/stocks/hold-cipla-may-test-rs-700-vijay-chopra-1002781.html
468,"Buy Cipla, Lupin, M&M Financial Services: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/stocks/buy-cipla-lupin-mm-financial-services-sudarshan-sukhani-1002945.html
469,"Buy, sell, hold: 10 crucial stocks to watch out post Q3 results",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-10-crucial-stocks-to-watch-out-post-q3-results-1002763.html
470,"Sensex up 150 pts, Nifty reclaims 8800 after 2-day consolidation",https://www.moneycontrol.com/news/business/markets/sensex150-pts-nifty-reclaims-8800-after-2-day-consolidation-1002967.html
471,"Stocks in news: Hero Moto, Lupin, Cipla, Idea, Axis, Thermax",https://www.moneycontrol.com/news/business/stocks/stocksnews-hero-moto-lupin-cipla-idea-axis-thermax-1002956.html
472,Dr Reddy's US launch of cancer drug delayed over compliance woes,https://www.moneycontrol.com/news/business/companies/dr-reddys-us-launchcancer-drug-delayed-over-compliance-woes-1002786.html
473,Cipla Q3 profit up 44% at Rs 375 cr on strong operational income,https://www.moneycontrol.com/news/business/earnings/cipla-q3-profit44-at-rs-375-crstrong-operational-income-1003016.html
474,"Stocks in news: Infosys, Axis, Tata Steel, Bharti, Quess, Titan",https://www.moneycontrol.com/news/business/stocks/stocksnews-infosys-axis-tata-steel-bharti-quess-titan-1003419.html
475,"Cipla Q3 profit seen up 5%; US, India & EMs may lift revenue 20%",https://www.moneycontrol.com/news/business/earnings/cipla-q3-profit-seen5-us-indiaems-may-lift-revenue-20-1003478.html
476,"Buy, sell, hold: 7 stocks analysts are watching out",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-7-stocks-analystswatching-out-1001456.html
477,"Buy Hindustan Unilever, Cipla: Rahul Mohindar",https://www.moneycontrol.com/news/business/stocks/buy-hindustan-unilever-cipla-rahul-mohindar-1001831.html
478,Good Q3 but Dr Reddy's still far from sustainable growth: Expert,https://www.moneycontrol.com/news/business/earnings/good-q3dr-reddys-still-farsustainable-growth-expert-1001909.html
479,"Week ahead: RBI policy, Q3 earnings may decide market trend",https://www.moneycontrol.com/news/business/markets/week-ahead-rbi-policy-q3-earnings-may-decide-market-trend-1002008.html
480,"Buy Sintex Industries, Cipla: Sandeep Wagle",https://www.moneycontrol.com/news/business/stocks/buy-sintex-industries-cipla-sandeep-wagle-948503.html
481,"Sensex volatile; Cipla & Bank of Baroda gain 3%, Glenmark up 4%",https://www.moneycontrol.com/news/business/markets/sensex-volatile-ciplabankbaroda-gain-3-glenmark4-948736.html
482,"Sell Strides Shasun, Cipla; buy Tata Communications: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/sell-strides-shasun-cipla-buy-tata-communications-rajat-bose-949418.html
483,"Stocks in news: M&M, Cipla, Apar, Sona Koyo, Marico, Tata Global",https://www.moneycontrol.com/news/business/stocks/stocksnews-mm-cipla-apar-sona-koyo-marico-tata-global-949373.html
484,Looking for bigger partnership with Cipla: Serum Institute,https://www.moneycontrol.com/news/business/companies/looking-for-bigger-partnershipcipla-serum-institute-943972.html
485,"Sensex, Nifty continue to fall; Bharti, Cipla, HUL gainers",https://www.moneycontrol.com/news/business/markets/sensex-nifty-continue-to-fall-bharti-cipla-hul-gainers-944342.html
486,"Nifty holds 8400 amid pressure; Mindtree sinks 2%, Cipla jumps",https://www.moneycontrol.com/news/business/markets/nifty-holds-8400-amid-pressure-mindtree-sinks-2-cipla-jumps-944365.html
487,"Stocks in news: Tata Steel, Axis, Uttam Galva, Hind Zinc, Cipla",https://www.moneycontrol.com/news/business/stocks/stocksnews-tata-steel-axis-uttam-galva-hind-zinc-cipla-944779.html
488,Cipla arm to sell stake in Four M Propack to Shriji Polymers,https://www.moneycontrol.com/news/business/companies/cipla-arm-to-sell-stakefour-m-propack-to-shriji-polymers-944933.html
489,Cipla's influenza drug gets WHO pre-qualification,https://www.moneycontrol.com/news/business/companies/ciplas-influenza-drug-gets-who-pre-qualification-945302.html
490,Cipla Q3 PAT seen up 8.2% to Rs 383.4 cr: ICICI Securities,https://www.moneycontrol.com/news/business/earnings/cipla-q3-pat-seen82-to-rs-3834-cr-icici-securities-946431.html
491,Q3 results: Five trends to watch out from Indian drugmakers,https://www.moneycontrol.com/news/business/companies/q3-results-five-trends-to-watch-outindian-drugmakers-946328.html
492,Cipla Q3 PAT may dip 2.6% to Rs 345 cr: KR Choksey,https://www.moneycontrol.com/news/business/earnings/cipla-q3-pat-may-dip-26-to-rs-345-cr-kr-choksey-946732.html
493,"Sell Glenmark; buy Cipla, Cummins, AIA Engineering: Thacker",https://www.moneycontrol.com/news/business/stocks/sell-glenmark-buy-cipla-cummins-aia-engineering-thacker-946823.html
494,"Buy Tata Communications 680 Call, sell 720 Call: VK Sharma",https://www.moneycontrol.com/news/business/stocks/buy-tata-communications-680-call-sell-720-call-vk-sharma-946824.html
495,"Nifty gains for 3rd day; Trump views drag pharma, Infosys soars",https://www.moneycontrol.com/news/business/markets/nifty-gains-for-3rd-day-trump-views-drag-pharma-infosys-soars-942191.html
496,Top buzzing stocks to trade on January 12,https://www.moneycontrol.com/news/business/stocks/top-buzzing-stocks-to-tradejanuary-12-940788.html
497,"Buy, sell, hold: 14 stocks that you can focus today",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-14-stocks-that-you-can-focus-today-940659.html
498,Indian drug market growth moderates to 7.2% in December,https://www.moneycontrol.com/news/business/companies/indian-drug-market-growth-moderates-to-72december--941747.html
499,"Buy, sell, hold: 9 pharma & media stocks that you may focus",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-9-pharmamedia-stocks-that-you-may-focus-940041.html
500,"Expect slowdown in realty, stress in banking system: Neelkanth",https://www.moneycontrol.com/news/business/markets/expect-slowdownrealty-stressbanking-system-neelkanth-940363.html
501,"Sensex opens flat, Nifty below 8200; Tata Motors, ONCG gainers",https://www.moneycontrol.com/news/business/markets/sensex-opens-flat-nifty-below-8200-tata-motors-oncg-gainers-939866.html
502,PEs pull out record &#36;10.3 bn after solid show in 2016,https://www.moneycontrol.com/news/business/companies/pes-pull-out-record-36103-bn-after-solid-show2016-939355.html
503,"Nifty reclaims 8150, Sensex climbs over 150 pts; ITC, ICICI gain",https://www.moneycontrol.com/news/business/markets/nifty-reclaims-8150-sensex-climbs-over-150-pts-itc-icici-gain-939154.html
504,Here are Deven Choksey's top trading ideas,https://www.moneycontrol.com/news/business/stocks/heredeven-chokseys-top-trading-ideas-937461.html
505,"Santa rally on D-St; Nifty nears 8100, Sensex up over 100 pts",https://www.moneycontrol.com/news/business/markets/santa-rallyd-st-nifty-nears-8100-sensexover-100-pts-937734.html
506,"Sensex up over 100 pts, Nifty reclaims 7950; IT & pharma lead",https://www.moneycontrol.com/news/business/markets/sensexover-100-pts-nifty-reclaims-7950-itpharma-lead-937969.html
507,"Nifty opens above 7900, Sensex firm; Tata Steel, ITC, Cipla up",https://www.moneycontrol.com/news/business/markets/nifty-opens-above-7900-sensex-firm-tata-steel-itc-cipla-up-938000.html
508,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-938157.html
509,Top buzzing midcap stocks to trade on December 26,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-tradedecember-26-938197.html
510,"Buy BHEL, Asian Paints; stay away from Cipla: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/stocks/buy-bhel-asian-paints-stay-awaycipla-sudarshan-sukhani-938203.html
511,"Sensex, Nifty still under pressure; HUL, Reliance gainers",https://www.moneycontrol.com/news/business/markets/sensex-nifty-still-under-pressure-hul-reliance-gainers-938212.html
512,"Nifty at over 7-month low, tests 7900; Sensex tanks 250 pts",https://www.moneycontrol.com/news/business/markets/nifty-at-over-7-month-low-tests-7900-sensex-tanks-250-pts-938236.html
513,Here is why  SP Tulsian continues to be positive on market,https://www.moneycontrol.com/news/business/stocks/here-is-sp-tulsian-continues-to-be-positivemarket-938389.html
514,Sensex snap 7-day losing streak ahead of Christmas holiday,https://www.moneycontrol.com/news/business/markets/sensex-snap-7-day-losing-streak-aheadchristmas-holiday-938396.html
515,Cipla shares gain 4% on UK MHRA nod for generic asthma drug,https://www.moneycontrol.com/news/business/stocks/cipla-shares-gain-4uk-mhra-nod-for-generic-asthma-drug-938313.html
516,Top buzzing midcap stocks to trade on December 23,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-tradedecember-23-938506.html
517,"Sell HDFC Bank, Cipla: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/sell-hdfc-bank-cipla-rajat-bose-938545.html
518,"Sell IndusInd Bank, DCB Bank, Cipla: Mitesh Thacker",https://www.moneycontrol.com/news/business/stocks/sell-indusind-bank-dcb-bank-cipla-mitesh-thacker-938554.html
519,"Stocks in news: Tata Motors, Sun Pharma, Wockhardt, InterGlobe",https://www.moneycontrol.com/news/business/stocks/stocksnews-tata-motors-sun-pharma-wockhardt-interglobe-936967.html
520,"Cipla seeks shareholders nod to raise Rs 4,000 crore",https://www.moneycontrol.com/news/business/companies/cipla-seeks-shareholders-nod-to-raise-rs-4000-crore-937032.html
521,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar--937142.html
522,Cipla gets USFDA nod for lipid regulating tablets,https://www.moneycontrol.com/news/business/companies/cipla-gets-usfda-nod-for-lipid-regulating-tablets-937178.html
523,"Holiday spirit to keep market dull, quality stock-picking likely",https://www.moneycontrol.com/news/business/markets/holiday-spirit-to-keep-market-dull-quality-stock-picking-likely-926480.html
524,Iranian JV: Cipla's Netherlands arm to invest up to euro 16.8mn,https://www.moneycontrol.com/news/business/companies/iranian-jv-ciplas-netherlands-arm-to-investto-euro-168mn-926861.html
525,"Stocks in news: Cipla, Gitanjali, Mandhana Retail, NALCO, Jagran",https://www.moneycontrol.com/news/business/stocks/stocksnews-cipla-gitanjali-mandhana-retail-nalco-jagran-927013.html
526,Cipla gets USFDA approval for anti-hepatitis B drug; shares gain,https://www.moneycontrol.com/news/business/stocks/cipla-gets-usfda-approval-for-anti-hepatitis-b-drug-shares-gain-917552.html
527,Cipla gets USFDA nod for Hepatitis B treatment drug,https://www.moneycontrol.com/news/business/companies/cipla-gets-usfda-nod-for-hepatitis-b-treatment-drug-917574.html
528,"Stocks in news: Tata Steel, Divis Labs, IVRCL, Prestige Estate",https://www.moneycontrol.com/news/business/stocks/stocksnews-tata-steel-divis-labs-ivrcl-prestige-estate-917592.html
529,Buy Cipla; target of Rs 700: Ajcon Global,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-700-ajcon-global-918161.html
530,"Buy Adani Ports, Tata Elxsi; sell Tata Steel: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-adani-ports-tata-elxsi-sell-tata-steel-ashwani-gujral-918896.html
531,"Buy Coffee Day, Cipla; sell India Cements, DHFL: Gujral",https://www.moneycontrol.com/news/business/stocks/buy-coffee-day-cipla-sell-india-cements-dhfl-gujral-918933.html
532,Delhi HC strikes down ban on 344 fixed-dose combination drugs,https://www.moneycontrol.com/news/business/companies/delhi-hc-strikes-down-ban344-fixed-dose-combination-drugs-919838.html
533,"Surprise, surprise! Pharma stocks beat peers and here's how",https://www.moneycontrol.com/news/business/markets/surprise-surprise-pharma-stocks-beat-peersheres-how-919552.html
534,Cipla appoints Ireena Vittal as independent director,https://www.moneycontrol.com/news/business/companies/cipla-appoints-ireena-vittal-as-independent-director-920566.html
535,"Sensex, Nifty continue to climb; pharma stocks down, auto up",https://www.moneycontrol.com/news/business/markets/sensex-nifty-continue-to-climb-pharma-stocks-down-auto-up-920596.html
536,"Buy Tech Mahindra, JSW Steel, Cipla: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-tech-mahindra-jsw-steel-cipla-ashwani-gujral-920902.html
537,"Nifty hovers around 8100, Sensex unsteady;banks fall on RBI move",https://www.moneycontrol.com/news/business/markets/nifty-hovers-around-8100-sensex-unsteadybanks-fallrbi-move-920901.html
538,"Stocks in news: Cipla, GAIL, Tata Elxsi, Aurobindo, Ricoh, Uflex",https://www.moneycontrol.com/news/business/stocks/stocksnews-cipla-gail-tata-elxsi-aurobindo-ricoh-uflex-920909.html
539,"Sell Eicher Motors; buy Cipla, Sonata Software: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/sell-eicher-motors-buy-cipla-sonata-software-ashwani-gujral-927677.html
540,"Buy, sell, hold: 5 stocks that analysts are watching out",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-5-stocks-that-analystswatching-out-927900.html
541,Cipla divests 16.7% stake in Chase Pharma to Allergan,https://www.moneycontrol.com/news/business/companies/cipla-divests-167-stakechase-pharma-to-allergan-928168.html
542,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-928216.html
543,Cipla UK arm sells entire stake in Chase Pharma to Allergen unit,https://www.moneycontrol.com/news/business/companies/cipla-uk-arm-sells-entire-stakechase-pharma-to-allergen-unit-928218.html
544,Buy Cipla; target of Rs 630: Khambatta Securities,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-630-khambatta-securities-928928.html
545,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-929275.html
546,"Nifty opens below 8100, Sensex flat; Tata Motors, ITC laggards",https://www.moneycontrol.com/news/business/markets/nifty-opens-below-8100-sensex-flat-tata-motors-itc-laggards-929398.html
547,CEOs of pharma cos to discuss key challenges within industry,https://www.moneycontrol.com/news/business/companies/ceospharma-cos-to-discuss-key-challenges-within-industry-929514.html
548,Buy Cipla; target of Rs 616: KR Choksey,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-616-kr-choksey-929558.html
549,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-929620.html
550,"Nifty ends below 8100 for 1st time since June 27, Tata Motors up",https://www.moneycontrol.com/news/business/markets/nifty-ends-below-8100-for-1st-time-since-june-27-tata-motors-up-929585.html
551,"Sensex, Nifty wobbly; IT index in red, metal & bank gainers",https://www.moneycontrol.com/news/business/markets/sensex-nifty-wobbly-it-indexred-metalbank-gainers-929651.html
552,Rising US approvals to boost earnings for pharma: IDFC Sec,https://www.moneycontrol.com/news/business/markets/rising-us-approvals-to-boost-earnings-for-pharma-idfc-sec-929968.html
553,"Nifty remains above 8150, Sensex steady; Midcap index up over 1%",https://www.moneycontrol.com/news/business/markets/nifty-remains-above-8150-sensex-steady-midcap-indexover-1-929992.html
554,Buy Cipla; target of Rs 600: Axis Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-600-axis-direct-930005.html
555,'Indian pharma's focus on acquisitions to limit deleveraging',https://www.moneycontrol.com/news/business/companies/indian-pharmas-focusacquisitions-to-limit-deleveraging-930303.html
556,"Prefer Cipla, Aurobindo Pharma: Gaurang Shah",https://www.moneycontrol.com/news/business/stocks/prefer-cipla-aurobindo-pharma-gaurang-shah-930940.html
557,"Buy Cipla, Bank fo India, HPCL: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-cipla-bank-fo-india-hpcl-ashwani-gujral-931378.html
558,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-931372.html
559,"Sensex zooms 400 pts, Nifty strong; Infosys, Maruti drag 1%",https://www.moneycontrol.com/news/business/markets/sensex-zooms-400-pts-nifty-strong-infosys-maruti-drag-1-931401.html
560,Cipla shares jump over 7% post Q2 results,https://www.moneycontrol.com/news/business/stocks/cipla-shares-jump-over-7-post-q2-results-931466.html
561,Trump's 'Make in US' plan a worry for pharma cos: Surajit Pal,https://www.moneycontrol.com/news/business/markets/trumps-makeus-planworry-for-pharma-cos-surajit-pal-931474.html
562,"Cipla, Power Grid, UCO Bank, JK Tyres among stocks in focus",https://www.moneycontrol.com/news/business/stocks/cipla-power-grid-uco-bank-jk-tyres-among-stocksfocus-931555.html
563,"Market may recover on global cues; Cipla, Sun Pharma in focus",https://www.moneycontrol.com/news/business/markets/market-may-recoverglobal-cues-cipla-sun-pharmafocus-931549.html
564,"Stocks in news: Sun Pharma, Tata Steel, Cipla, Parag Milk, UCO",https://www.moneycontrol.com/news/business/stocks/stocksnews-sun-pharma-tata-steel-cipla-parag-milk-uco-931503.html
565,Cipla Q2 net shrinks 35% to Rs 354 crore,https://www.moneycontrol.com/news/business/earnings/cipla-q2-net-shrinks-35-to-rs-354-crore-931647.html
566,"Cipla Q2 profit falls 35%, US & India drive revenue growth",https://www.moneycontrol.com/news/business/earnings/cipla-q2-profit-falls-35-usindia-drive-revenue-growth-931577.html
567,"Stocks in news: Lupin, InterGlobe, Dilip, Biocon, MRPL, VA Tech",https://www.moneycontrol.com/news/business/stocks/stocksnews-lupin-interglobe-dilip-biocon-mrpl-va-tech-931887.html
568,"Cipla Q2 profit seen down 13%, lower Nexium sales may hit margin",https://www.moneycontrol.com/news/business/earnings/cipla-q2-profit-seen-down-13-lower-nexium-sales-may-hit-margin-932147.html
569,"Nifty hovers around 8500, Sensex flat; Sun Pharma, Maruti down",https://www.moneycontrol.com/news/business/markets/nifty-hovers-around-8500-sensex-flat-sun-pharma-maruti-down-932312.html
570,"US election, quarterly earnings to keep investors busy next week",https://www.moneycontrol.com/news/business/markets/us-election-quarterly-earnings-to-keep-investors-busy-next-week-951052.html
571,Ind-Ra puts Cipla ratings on negative watch; outlook stable,https://www.moneycontrol.com/news/business/companies/ind-ra-puts-cipla-ratingsnegative-watch-outlook-stable-951158.html
572,Top buzzing midcap stocks to trade on November 4,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-tradenovember-4-951483.html
573,"Sun Pharma falls 7%, sector under pressure on US probe fear",https://www.moneycontrol.com/news/business/stocks/sun-pharma-falls-7-sector-under-pressureus-probe-fear-951126.html
574,"Sensex, Nifty open in green; ITC surges 5%, Sun Pharma slumps 7%",https://www.moneycontrol.com/news/business/markets/sensex-nifty-opengreen-itc-surges-5-sun-pharma-slumps-7-951592.html
575,"Nifty opens below 8500, Sensex volatile; ONGC, Tata Motors drag",https://www.moneycontrol.com/news/business/markets/nifty-opens-below-8500-sensex-volatile-ongc-tata-motors-drag-952121.html
576,Go long in M&M; Cipla can slide to Rs 555: Prakash Gaba,https://www.moneycontrol.com/news/business/stocks/go-longmm-cipla-can-slide-to-rs-555-prakash-gaba-952410.html
577,"Dr Reddy's Labs top pick on decline, says Sanjiv Bhasin",https://www.moneycontrol.com/news/business/stocks/dr-reddys-labs-top-pickdecline-says-sanjiv-bhasin-954161.html
578,"Buy, sell, hold: 12 stocks to focus before it's too late",https://www.moneycontrol.com/news/business/stocks/buy-sell-hold-12-stocks-to-focus-before-its-too-late-954548.html
579,"Sensex, Nifty open flat; Tata group stocks fall on Mistry's exit",https://www.moneycontrol.com/news/business/markets/sensex-nifty-open-flat-tata-group-stocks-fallmistrys-exit-954721.html
580,"In blow to pharmas, SC dismisses plea against 2014 notification",https://www.moneycontrol.com/news/business/companies/in-blow-to-pharmas-sc-dismisses-plea-against-2014-notification-954689.html
581,"Sell Axis Bank, buy Dr Reddy's, Bharat Financial: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/sell-axis-bank-buy-dr-reddys-bharat-financial-rajat-bose-955396.html
582,Cipla Q2 PAT seen up 11.2% to Rs 406 cr: Centrum,https://www.moneycontrol.com/news/business/earnings/cipla-q2-pat-seen112-to-rs-406-cr-centrum-933643.html
583,Cipla signs deal to set up first biosimilars unit in S Africa,https://www.moneycontrol.com/news/business/companies/cipla-signs-deal-to-setfirst-biosimilars-units-africa-956839.html
584,"Sensex, Nifty sluggish; HUL falls 2%, IT index in red on Q2 nos",https://www.moneycontrol.com/news/business/markets/sensex-nifty-sluggish-hul-falls-2-it-indexredq2-nos-957175.html
585,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-957432.html
586,"Nifty ends below 8600, Sensex sheds 439 pts; HDFC, RIL fall 3-4%",https://www.moneycontrol.com/news/business/markets/nifty-ends-below-8600-sensex-sheds-439-pts-hdfc-ril-fall-3-4-957437.html
587,Top buzzing midcap stocks to trade on October 13,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-tradeoctober-13-957521.html
588,"Sell HDFC Bank; buy Cipla, Infosys: Mitesh Thacker",https://www.moneycontrol.com/news/business/stocks/sell-hdfc-bank-buy-cipla-infosys-mitesh-thacker-957557.html
589,"Sell Union Bank, ICICI Bank; buy Cipla: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/sell-union-bank-icici-bank-buy-cipla-ashwani-gujral-957559.html
590,"Sensex slumps over 200 pts, Nifty below 8650: TCS falls 1%",https://www.moneycontrol.com/news/business/markets/sensex-slumps-over-200-pts-nifty-below-8650-tcs-falls-1-957586.html
591,"Keep an eye on: IndusInd Bk, TCS, Cipla, Rel Infra, GRUH Fin",https://www.moneycontrol.com/news/business/stocks/keepeye-on-indusind-bk-tcs-cipla-rel-infra-gruh-fin-957619.html
592,"Buy, sell or hold: 9 stocks that analysts are bullish on",https://www.moneycontrol.com/news/business/stocks/buy-sell-or-hold-9-stocks-that-analystsbullish-on-957627.html
593,"Stocks in news: M&M, Sterlite Tech, Cipla, Titan, Capri Global",https://www.moneycontrol.com/news/business/stocks/stocksnews-mm-sterlite-tech-cipla-titan-capri-global-957615.html
594,Cipla receives EIR Report from USFDA for Indore facility,https://www.moneycontrol.com/news/business/companies/cipla-receives-eir-reportusfda-for-indore-facility-957655.html
595,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-958034.html
596,"Sensex, Nifty end flat amid thin volume; Reliance, Bharti drag",https://www.moneycontrol.com/news/business/markets/sensex-nifty-end-flat-amid-thin-volume-reliance-bharti-drag-958012.html
597,"Sensex, Nifty sluggish; HDFC & SBI down, Infosys gains 1%",https://www.moneycontrol.com/news/business/markets/sensex-nifty-sluggish-hdfcsbi-down-infosys-gains-1-958102.html
598,"Sensex flat, Nifty holds 8700; TCS, Bharti, ONGC laggards",https://www.moneycontrol.com/news/business/markets/sensex-flat-nifty-holds-8700-tcs-bharti-ongc-laggards-958154.html
599,"Sensex up over 100pts, Nifty above 8700; ITC, Tata Steel gain 1%",https://www.moneycontrol.com/news/business/markets/sensexover-100pts-nifty-above-8700-itc-tata-steel-gain-1-958175.html
600,Here are top 10 stocks to keep an eye on October 10,https://www.moneycontrol.com/news/business/stocks/heretop-10-stocks-to-keepeyeoctober-10-958208.html
601,Earnings likely to surprise; expect 6-7% topline growth: Expert,https://www.moneycontrol.com/news/business/markets/earnings-likely-to-surprise-expect-6-7-topline-growth-expert-958329.html
602,"Nifty holds 8750, Sensex firm; IT stocks under pressure",https://www.moneycontrol.com/news/business/markets/nifty-holds-8750-sensex-firm-it-stocks-under-pressure-958858.html
603,"Buy, sell or hold: Watch out for these 11 stocks today",https://www.moneycontrol.com/news/business/stocks/buy-sell-or-hold-watch-out-for11-stocks-today-958940.html
604,"Buy Petronet LNG, United Breweries, Cipla: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-petronet-lng-united-breweries-cipla-ashwani-gujral-959568.html
605,"Nifty opens above 8750, Sensex climbs over 100 pts; Adani gains",https://www.moneycontrol.com/news/business/markets/nifty-opens-above-8750-sensex-climbs-over-100-pts-adani-gains-959706.html
606,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-960472.html
607,Cipla gets four USFDA observations for three Goa facilities,https://www.moneycontrol.com/news/business/companies/cipla-gets-four-usfda-observations-for-three-goa-facilities-960484.html
608,"Nifty ends above 8600; Tata Steel & SBI up, ITC down 1%",https://www.moneycontrol.com/news/business/markets/nifty-ends-above-8600-tata-steelsbi-up-itc-down-1-960449.html
609,Cipla loses 6% on 4 observations from USFDA for 3 Goa units,https://www.moneycontrol.com/news/business/stocks/cipla-loses-64-observationsusfda-for-3-goa-units-960201.html
610,"Sell Cipla, Wockhardt; buy United Spirits: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/sell-cipla-wockhardt-buy-united-spirits-ashwani-gujral-960537.html
611,"Nifty hovers around 8600, Sensex flat; BHEL, SBI, Infosys gain",https://www.moneycontrol.com/news/business/markets/nifty-hovers-around-8600-sensex-flat-bhel-sbi-infosys-gain-960573.html
612,"Buy Apollo Tyres, Reliance Capital, Cipla: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/stocks/buy-apollo-tyres-reliance-capital-cipla-sudarshan-sukhani-960839.html
613,Domestic pharma firms facing challenging environment: Cipla,https://www.moneycontrol.com/news/business/companies/domestic-pharma-firms-facing-challenging-environment-cipla-960929.html
614,"Stocks in news: ICICI Prudential, Kotak Mah, MCX, Pidilite, IOC",https://www.moneycontrol.com/news/business/stocks/stocksnews-icici-prudential-kotak-mah-mcx-pidilite-ioc-960867.html
615,Cipla targeting 10-12% growth in next 2-3 years: CEO,https://www.moneycontrol.com/news/business/companies/cipla-targeting-10-12-growthnext-2-3-years-ceo-960890.html
616,Don‘t expect big returns from large-cap pharma: Surajit Pal,https://www.moneycontrol.com/news/business/stocks/donâ€™t-expect-big-returnslarge-cap-pharma-surajit-pal-961355.html
617,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-961595.html
618,Here are a few investment ideas from Prakash Diwan,https://www.moneycontrol.com/news/business/stocks/here-arefew-investment-ideasprakash-diwan-962126.html
619,"Buy Cipla, Reliance Infra, ONGC; sell Mindtree: Gaurav Bissa",https://www.moneycontrol.com/news/business/stocks/buy-cipla-reliance-infra-ongc-sell-mindtree-gaurav-bissa-963675.html
620,"Buy Cipla, Wockhardt, Power Grid: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/buy-cipla-wockhardt-power-grid-rajat-bose-963724.html
621,Here are Rahul Arora's few investment ideas,https://www.moneycontrol.com/news/business/stocks/hererahul-aroras-few-investment-ideas-963699.html
622,"Buy Cipla; sell Reliance Comm, Tata Steel: Mitesh Thacker",https://www.moneycontrol.com/news/business/stocks/buy-cipla-sell-reliance-comm-tata-steel-mitesh-thacker-964285.html
623,"Buy Amara Raja, Divis Lab; sell Indo Count Industries: Sukhani",https://www.moneycontrol.com/news/business/stocks/buy-amara-raja-divis-lab-sell-indo-count-industries-sukhani-964726.html
624,"Buy Amara Raja Batteries, Cipla, Ajanta Pharma: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-amara-raja-batteries-cipla-ajanta-pharma-ashwani-gujral-964776.html
625,"Aurobindo Pharma may test Rs 814, Cipla Rs 594: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/aurobindo-pharma-may-test-rs-814-cipla-rs-594-rajat-bose-964780.html
626,"Buy Delta Corp, Cipla; sell India Cements: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-delta-corp-cipla-sell-india-cements-ashwani-gujral-965491.html
627,"Buy Cipla 600 Call, Cadila Healthcare 300 Call: VK Sharma",https://www.moneycontrol.com/news/business/stocks/buy-cipla-600-call-cadila-healthcare-300-call-vk-sharma-965883.html
628,"Buy Cipla, Rallis India, UCO Bank: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-cipla-rallis-india-uco-bank-ashwani-gujral-966133.html
629,"To focus on dengue vaccine, pneumonia solutions: Serum Institute",https://www.moneycontrol.com/news/business/companies/to-focusdengue-vaccine-pneumonia-solutions-serum-institute-966566.html
630,"Buy Jain Irrigation , Cipla, UltraTech Cement: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-jain-irrigationcipla-ultratech-cement-ashwani-gujral-967606.html
631,Here are some trading bets from Mehraboon Irani,https://www.moneycontrol.com/news/business/stocks/heresome-trading-betsmehraboon-irani-968889.html
632,"Buy Cipla, Engineers India, Voltas: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-cipla-engineers-india-voltas-ashwani-gujral-970416.html
633,"Sell BHEL, Godrej Industries; buy Cipla: Sandeep Wagle",https://www.moneycontrol.com/news/business/stocks/sell-bhel-godrej-industries-buy-cipla-sandeep-wagle-970460.html
634,"Buy Cipla, Maruti Suzuki, Zee Entertainment: Chandan Taparia",https://www.moneycontrol.com/news/business/stocks/buy-cipla-maruti-suzuki-zee-entertainment-chandan-taparia-970482.html
635,"Buy Cummins India, Cipla, JK Tyre: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-cummins-india-cipla-jk-tyre-ashwani-gujral-970483.html
636,"Next 12 months good for equities; avoid pharma, PSU banks: Ambit",https://www.moneycontrol.com/news/business/markets/next-12-months-good-for-equities-avoid-pharma-psu-banks-ambit-971036.html
637,"Cipla may test Rs 750, Bharat Forge Rs 1400: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/cipla-may-test-rs-750-bharat-forge-rs-1400-ashwani-gujral-971530.html
638,Indian market in 'Goldilocks' situation; like hsg fin cos: IL&FS,https://www.moneycontrol.com/news/business/markets/indian-marketgoldilocks-situation-like-hsg-fin-cos-ilfs-971491.html
639,Buy Kotak Mahindra Bank above Rs 787; sell Lupin: Mitesh Thacker,https://www.moneycontrol.com/news/business/stocks/buy-kotak-mahindra-bank-above-rs-787-sell-lupin-mitesh-thacker-971800.html
640,Keep HDFC in portfolio: Vijay Chopra,https://www.moneycontrol.com/news/business/stocks/keep-hdfcportfolio-vijay-chopra-971969.html
641,"Buy LIC Housing, PNB, IGL; Biocon may hit Rs 970: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-lic-housing-pnb-igl-biocon-may-hit-rs-970-ashwani-gujral-972052.html
642,Buy Cipla India; target of Rs 600: Axis Direct,https://www.moneycontrol.com/news/business/stocks/buy-cipla-india-targetrs-600-axis-direct-934240.html
643,Buy Cipla; target of Rs 616: KR Choksey,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-616-kr-choksey-934247.html
644,Hold Cipla; target of Rs 480: Edelweiss,https://www.moneycontrol.com/news/business/stocks/hold-cipla-targetrs-480-edelweiss-934249.html
645,"Buy Cipla; sell Wipro, GAIL India: Mitesh Thacker",https://www.moneycontrol.com/news/business/stocks/buy-cipla-sell-wipro-gail-india-mitesh-thacker-972273.html
646,Here are some stock ideas from SP Tulsian,https://www.moneycontrol.com/news/business/stocks/heresome-stock-ideassp-tulsian-972425.html
647,"Stocks to watch out for: Interglobe Aviation, Just Dial, Cipla",https://www.moneycontrol.com/news/business/stocks/stocks-to-watch-out-for-interglobe-aviation-just-dial-cipla-972493.html
648,Tulsian: This is what you should be betting on,https://www.moneycontrol.com/news/business/markets/tulsian-this-isyou-should-be-betting-on-972536.html
649,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-972639.html
650,"Buy Cipla, Reliance Capital; sell TCS: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-cipla-reliance-capital-sell-tcs-ashwani-gujral-972650.html
651,Top buzzing midcap stocks to trade on August 16,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-tradeaugust-16-972699.html
652,Stocks that must be on your radar in trade today,https://www.moneycontrol.com/news/business/stocks/stocks-that-must-beyour-radartrade-today-972774.html
653,Cipla names Samina Vaziralli as Executive Vice-Chairman,https://www.moneycontrol.com/news/business/companies/cipla-names-samina-vaziralli-as-executive-vice-chairman-972951.html
654,"Cipla Q1 profit down 44%, US biz drags revenue; MD to step down",https://www.moneycontrol.com/news/business/earnings/cipla-q1-profit-down-44-us-biz-drags-revenue-md-to-step-down-934613.html
655,"Cipla Q1 profit seen down 41% to Rs 385 cr, revenue may be flat",https://www.moneycontrol.com/news/business/earnings/cipla-q1-profit-seen-down-41-to-rs-385-cr-revenue-may-be-flat-934900.html
656,"Buy Dr Reddy's Labs, Cipla, Biocon: Sanjiv Bhasin",https://www.moneycontrol.com/news/business/stocks/buy-dr-reddys-labs-cipla-biocon-sanjiv-bhasin-974165.html
657,"Buy Fortis Healthcare, Cipla; sell Siemens: Mitesh Thacker",https://www.moneycontrol.com/news/business/stocks/buy-fortis-healthcare-cipla-sell-siemens-mitesh-thacker-976009.html
658,Here are a few stocks ideas from Prakash Diwan,https://www.moneycontrol.com/news/business/stocks/here-arefew-stocks-ideasprakash-diwan-976819.html
659,"Buy Cadila Healthcare, Cipla: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/buy-cadila-healthcare-cipla-rajat-bose-979077.html
660,"Buy Hindustan Unilever, Cipla: Rahul Mohindar",https://www.moneycontrol.com/news/business/stocks/buy-hindustan-unilever-cipla-rahul-mohindar-979117.html
661,"Here's why Canara Bank, pharma cos, Texmaco Rail are in news",https://www.moneycontrol.com/news/business/stocks/herescanara-bank-pharma-cos-texmaco-rail-arenews-979128.html
662,"Nifty opens above 8550, Sensex firm; ITC up 1%, IT stocks down",https://www.moneycontrol.com/news/business/markets/nifty-opens-above-8550-sensex-firm-itc1-it-stocks-down-980396.html
663,"Buy Lupin, Cipla, Godfrey Phillips India, Escorts: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/buy-lupin-cipla-godfrey-phillips-india-escorts-rajat-bose-980399.html
664,"Here's why HPCL, Axis Bank, KPIT Tech, IIFL, MCX are in focus",https://www.moneycontrol.com/news/business/stocks/hereshpcl-axis-bank-kpit-tech-iifl-mcx-arefocus-980410.html
665,Cipla Q1 PAT seen up by 315% at Rs 335.9 cr: Religare Research,https://www.moneycontrol.com/news/business/earnings/cipla-q1-pat-seenby-315-at-rs-3359-cr-religare-research-936368.html
666,"Sensex reclaims 28000, Nifty firm; TCS falls 1% post Q1 nos",https://www.moneycontrol.com/news/business/markets/sensex-reclaims-28000-nifty-firm-tcs-falls-1-post-q1-nos-982073.html
667,"CLSA invests in Indiabulls Hsg & DLF, ups investment in Prestige",https://www.moneycontrol.com/news/business/markets/clsa-investsindiabulls-hsgdlf-ups-investmentprestige-982078.html
668,Cipla Q1 PAT seen up 522.4% to Rs 503.3 cr: Edelweiss,https://www.moneycontrol.com/news/business/earnings/cipla-q1-pat-seen5224-to-rs-5033-cr-edelweiss-936438.html
669,"Nifty below 8550, Sensex firm; Maruti, SBI gain 2%",https://www.moneycontrol.com/news/business/markets/nifty-below-8550-sensex-firm-maruti-sbi-gain-2-982318.html
670,"Sensex, Nifty sluggish; GAIL, Tata Motors, Asian Paints gainers",https://www.moneycontrol.com/news/business/markets/sensex-nifty-sluggish-gail-tata-motors-asian-paints-gainers-982386.html
671,"Q1 earnings: Which sectors will do well, which won't?",https://www.moneycontrol.com/news/business/earnings/q1-earnings-which-sectors-will-do-wellwont-936503.html
672,"Sensex 1-yr target at 28800, Q1 earnings to be flattish: Citi",https://www.moneycontrol.com/news/business/markets/sensex-1-yr-target-at-28800-q1-earnings-to-be-flattish-citi-983136.html
673,Gautam Chhaochharia overweight on pharma space,https://www.moneycontrol.com/news/business/stocks/gautam-chhaochharia-overweightpharma-space-983662.html
674,"Buy Aurobindo Pharma, United Spirits may test Rs 3200: Gujral",https://www.moneycontrol.com/news/business/stocks/buy-aurobindo-pharma-united-spirits-may-test-rs-3200-gujral-983663.html
675,"Nifty base case scenario at 7,700: UBS",https://www.moneycontrol.com/news/business/markets/nifty-base-case-scenario-at-7700-ubs-981514.html
676,"Cipla shares up 2%, to launch biotech facility in South Africa",https://www.moneycontrol.com/news/business/stocks/cipla-shares2-to-launch-biotech-facilitysouth-africa-983799.html
677,Cipla to invest Rs 590 cr for a biosimilars plant in S Africa,https://www.moneycontrol.com/news/business/companies/cipla-to-invest-rs-590-cr-forbiosimilars-plants-africa-983766.html
678,"Buy ILandFS Transportation, Cadila Health, Cipla: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/buy-ilandfs-transportation-cadila-health-cipla-rajat-bose-983805.html
679,"Pharma a no-no, but banks pass the test for Prabhudas Lilladher",https://www.moneycontrol.com/news/business/stocks/pharmano-nobanks-passtest-for-prabhudas-lilladher-983811.html
680,"Buy Cipla 520 Call, advises VK Sharma",https://www.moneycontrol.com/news/business/stocks/buy-cipla-520-call-advises-vk-sharma-983921.html
681,"Lupin, Cipla top picks from pharma space: Manoj Murlidharan",https://www.moneycontrol.com/news/business/stocks/lupin-cipla-top-pickspharma-space-manoj-murlidharan-984241.html
682,Here are Sanjiv Bhasin's top trading ideas,https://www.moneycontrol.com/news/business/stocks/heresanjiv-bhasins-top-trading-ideas-984659.html
683,Checkout: Auto stocks in focus post June sales nos,https://www.moneycontrol.com/news/business/stocks/checkout-auto-stocksfocus-post-june-sales-nos-985148.html
684,Here's why these stocks should be on your radar,https://www.moneycontrol.com/news/business/stocks/heresthese-stocks-should-beyour-radar-986029.html
685,Why pharma stocks can rally in July: SP Tulsian,https://www.moneycontrol.com/news/business/stocks/why-pharma-stocks-can-rallyjuly-sp-tulsian-986506.html
686,Top 10: Here are stocks that need to be on your radar today,https://www.moneycontrol.com/news/business/stocks/top-10-herestocks-that-need-to-beyour-radar-today-986741.html
687,"Brexit impact limited on pharma, US biz to offset risk: Analysts",https://www.moneycontrol.com/news/business/stocks/brexit-impact-limitedpharma-us-biz-to-offset-risk-analysts-987031.html
688,"Sensex, Nifty flat; SBI gains 1%, TCS & Infosys slip 1-3%",https://www.moneycontrol.com/news/business/markets/sensex-nifty-flat-sbi-gains-1-tcsinfosys-slip-1-3-987066.html
689,"Sensex, Nifty sluggish; Tata Motors, SBI & Lupin up 1-2%",https://www.moneycontrol.com/news/business/markets/sensex-nifty-sluggish-tata-motors-sbilupin1-2-987786.html
690,"Sensex, Nifty flat as investors jittery on Brexit vote;NTPC dips",https://www.moneycontrol.com/news/business/markets/sensex-nifty-flat-as-investors-jitterybrexit-votentpc-dips-987847.html
691,Cipla looks good for long term: Prakash Gaba,https://www.moneycontrol.com/news/business/stocks/cipla-looks-good-for-long-term-prakash-gaba-988414.html
692,"Buy Lupin for long term, says Parag Thakkar",https://www.moneycontrol.com/news/business/stocks/buy-lupin-for-long-term-says-parag-thakkar-988415.html
693,"Sensex, Nifty remain sluggish; Bajaj Auto up 1%, BHEL down",https://www.moneycontrol.com/news/business/markets/sensex-nifty-remain-sluggish-bajaj-auto1-bhel-down-988552.html
694,"Stocks to watch: HDFC, Cipla, IOC, Eros, Rolta, Tata Chemicals",https://www.moneycontrol.com/news/business/stocks/stocks-to-watch-hdfc-cipla-ioc-eros-rolta-tata-chemicals-988986.html
695,"Cipla in pact with Russian firm for HIV, Hepatitis C drugs",https://www.moneycontrol.com/news/business/companies/ciplapactrussian-firm-for-hiv-hepatitis-c-drugs-989039.html
696,Advise profit-booking for non-F&O PSU banks: SP Tulsian,https://www.moneycontrol.com/news/business/markets/advise-profit-booking-for-non-fo-psu-banks-sp-tulsian-989198.html
697,"Apollo Tyres may test Rs 158.50, Cipla Rs 497: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/apollo-tyres-may-test-rs-15850-cipla-rs-497-rajat-bose-990102.html
698,Super 6 stock ideas to liven up your trade,https://www.moneycontrol.com/news/business/stocks/super-6-stock-ideas-to-livenyour-trade--990097.html
699,"Global shocks aside, basic premise of bull market intact: Mehta",https://www.moneycontrol.com/news/business/markets/global-shocks-aside-basic-premisebull-market-intact-mehta-990679.html
700,"Buy Cipla 490 Call, says VK Sharma",https://www.moneycontrol.com/news/business/stocks/buy-cipla-490-call-says-vk-sharma-991174.html
701,"Cipla may test Rs 491, IPCA Labs Rs 477: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/cipla-may-test-rs-491-ipca-labs-rs-477-rajat-bose-991199.html
702,"Sensex rallies over 150 pts, Nifty reclaims 8250; BHEL, M&M up",https://www.moneycontrol.com/news/business/markets/sensex-rallies-over-150-pts-nifty-reclaims-8250-bhel-mm-up-991167.html
703,Cipla board approves appointment of Kedar Upadhye as GlobalCFO,https://www.moneycontrol.com/news/business/companies/cipla-board-approves-appointmentkedar-upadhye-as-globalcfo-991711.html
704,"Nifty struggles below 8250, Sensex sluggish; banks in focus",https://www.moneycontrol.com/news/business/markets/nifty-struggles-below-8250-sensex-sluggish-banksfocus-992433.html
705,"Sensex opens flat, Nifty below 8250; Lupin, GAIL, Cipla gain",https://www.moneycontrol.com/news/business/markets/sensex-opens-flat-nifty-below-8250-lupin-gail-cipla-gain-992535.html
706,"Stocks in news: Cipla, L&T, Jubilant Life, Guj Gas, Bharat Forge",https://www.moneycontrol.com/news/business/stocks/stocksnews-cipla-lt-jubilant-life-guj-gas-bharat-forge-992564.html
707,6 stocks that should do well today,https://www.moneycontrol.com/news/business/stocks/6-stocks-that-should-do-well-today-992920.html
708,"Remain invested in Cipla, says Prakash Gaba",https://www.moneycontrol.com/news/business/stocks/remain-investedcipla-says-prakash-gaba-993079.html
709,Cipla may move to Rs 500-550: Vijay Chopra,https://www.moneycontrol.com/news/business/stocks/cipla-may-move-to-rs-500-550-vijay-chopra-993097.html
710,Stempeutics gets DCGI nod for stem cell based product,https://www.moneycontrol.com/news/business/companies/stempeutics-gets-dcgi-nod-for-stem-cell-based-product-994513.html
711,'Anyone saying PSBs have turned around is selling you a lemon',https://www.moneycontrol.com/news/business/markets/anyone-saying-psbs-have-turned-around-is-selling-youlemon-994695.html
712,Buy Cipla; target of Rs 616: KR Choksey,https://www.moneycontrol.com/news/business/stocks/buy-cipla-targetrs-616-kr-choksey-994955.html
713,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-994993.html
714,"Nifty on a high: experts bet on bank, auto to lead rally",https://www.moneycontrol.com/news/business/markets/nifty-onhigh-experts-betbank-auto-to-lead-rally-995418.html
715,"Buy M&M Financial, Cipla; sell Biocon: Gaurav Bisa",https://www.moneycontrol.com/news/business/stocks/buy-mm-financial-cipla-sell-biocon-gaurav-bisa-995487.html
716,Accumulate Cipla; target of Rs 565: Emkay,https://www.moneycontrol.com/news/business/stocks/accumulate-cipla-targetrs-565-emkay-995849.html
717,"Nifty ends above 7900 ahead of expiry, Sensex up 576 pts",https://www.moneycontrol.com/news/business/markets/nifty-ends-above-7900-aheadexpiry-sensex576-pts-995723.html
718,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-995870.html
719,Top buzzing midcap stocks to trade on May 25,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-trademay-25-995954.html
720,"Buy IndusInd Bank, Havells India, Axis Bank: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-indusind-bank-havells-india-axis-bank-ashwani-gujral-996043.html
721,Here are some stock picks from SP Tulsian,https://www.moneycontrol.com/news/business/stocks/heresome-stock-pickssp-tulsian-995858.html
722,Expect 10-15 launches in the US this year: Cipla,https://www.moneycontrol.com/news/business/earnings/expect-10-15-launchesthe-us-this-year-cipla-995920.html
723,Cipla slips 7% on Q4 shocker; margins pressure may persist,https://www.moneycontrol.com/news/business/stocks/cipla-slips-7q4-shocker-margins-pressure-may-persist-995824.html
724,"Sensex, Nifty climb over 1%; ICICI Bank leads, Cipla tanks 7%",https://www.moneycontrol.com/news/business/markets/sensex-nifty-climb-over-1-icici-bank-leads-cipla-tanks-7-996053.html
725,"Fourth quarter earnings to keep Cipla, BoI, TechM in focus today",https://www.moneycontrol.com/news/business/stocks/fourth-quarter-earnings-to-keep-cipla-boi-techmfocus-today-996100.html
726,"Stocks in news: BoI, Tech Mah, Cipla, Ruchi Soya, VRL, Redington",https://www.moneycontrol.com/news/business/stocks/stocksnews-boi-tech-mah-cipla-ruchi-soya-vrl-redington-996112.html
727,Nifty may see sub-7700 near-term; upbeat on Tech Mah: Geojit,https://www.moneycontrol.com/news/business/markets/nifty-may-see-sub-7700-near-term-upbeattech-mah-geojit-996180.html
728,Cipla Q4 net disappoints at Rs 80cr; topline at Rs 3266cr,https://www.moneycontrol.com/news/business/earnings/cipla-q4-net-disappoints-at-rs-80cr-topline-at-rs-3266cr-996020.html
729,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-996360.html
730,"Cipla Q4 profit seen up 39%, likely to meet FY16 growth guidance",https://www.moneycontrol.com/news/business/earnings/cipla-q4-profit-seen39-likely-to-meet-fy16-growth-guidance-996500.html
731,"Buy Indiabulls Housing, CONCOR, M&M Financial: Ashwani Gujral",https://www.moneycontrol.com/news/business/stocks/buy-indiabulls-housing-concor-mm-financial-ashwani-gujral-996861.html
732,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-996811.html
733,"SBI, L&T results to set market trend, monsoon's pace on watch",https://www.moneycontrol.com/news/business/markets/sbi-lt-results-to-set-market-trend-monsoons-pacewatch-997138.html
734,Top buzzing midcap stocks to trade on May 20,https://www.moneycontrol.com/news/business/stocks/top-buzzing-midcap-stocks-to-trademay-20-997597.html
735,"Infosys, HDFC Bank, Aurobindo are top picks: R Sreesankar",https://www.moneycontrol.com/news/business/stocks/infosys-hdfc-bank-aurobindotop-picks-r-sreesankar-997470.html
736,"Sell L&T; Cipla may test Rs 504, Zee Ent Rs 424: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/sell-lt-cipla-may-test-rs-504-zee-ent-rs-424-rajat-bose-997768.html
737,"Sensex, Nifty rangebound; ICICI, Cipla, Bharti losers",https://www.moneycontrol.com/news/business/markets/sensex-nifty-rangebound-icici-cipla-bharti-losers-997706.html
738,"Buy DLF, Ashok Leyland, L&T Housing Finance: Chandan Taparia",https://www.moneycontrol.com/news/business/stocks/buy-dlf-ashok-leyland-lt-housing-finance-chandan-taparia-998037.html
739,Nifty unlikely to have many upsides from current levels: Ambit,https://www.moneycontrol.com/news/business/markets/nifty-unlikely-to-have-many-upsidescurrent-levels-ambit-998020.html
740,Six in Sixty: Stocks you should keep on your radar,https://www.moneycontrol.com/news/business/stocks/sixsixty-stocks-you-should-keepyour-radar-999660.html
741,"Buy Cipla, Bata; sell Cummins: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/stocks/buy-cipla-bata-sell-cummins-sudarshan-sukhani-1017690.html
742,"Cipla, favourite pick; like Sun Pharma: Pankaj Sharma",https://www.moneycontrol.com/news/business/stocks/cipla-favourite-pick-like-sun-pharma-pankaj-sharma-1018272.html
743,"Sensex, Nifty end lower; banks & IT drag, metals gain",https://www.moneycontrol.com/news/business/markets/sensex-nifty-end-lower-banksit-drag-metals-gain-1018963.html
744,"Buy Tata Steel, Cipla: Rahul Shah",https://www.moneycontrol.com/news/business/stocks/buy-tata-steel-cipla-rahul-shah-1019043.html
745,"Buy Century Textiles, Cipla: Sudarshan Sukhani",https://www.moneycontrol.com/news/business/stocks/buy-century-textiles-cipla-sudarshan-sukhani-1019137.html
746,"Nifty hovers around 7800, Sensex still in red; bank, IT drag",https://www.moneycontrol.com/news/business/markets/nifty-hovers-around-7800-sensex-stillred-bank-it-drag-1019112.html
747,Super Six stocks you can bet on May 2,https://www.moneycontrol.com/news/business/stocks/super-six-stocks-you-can-betmay-2-1019047.html
748,"Buy Sun TV, Cipla: Sameet Chavan",https://www.moneycontrol.com/news/business/stocks/buy-sun-tv-cipla-sameet-chavan-1019340.html
749,"Vedanta may test Rs 113.50, Cipla Rs 555: Rajat Bose",https://www.moneycontrol.com/news/business/stocks/vedanta-may-test-rs-11350-cipla-rs-555-rajat-bose-1020238.html
